Electrophysiological Role of Voltage-gated Sodium Channel B2 Subunits in the Heart. by Bao, Yangyang
 
 
Electrophysiological Role of Voltage-gated Sodium Channel 
β2 Subunits in the Heart 
by 
Yangyang Bao 
 
A dissertation submitted in partial fulfillment  
of the requirements for the degree of  
Doctor of Philosophy 
(Pharmacology) 
In the University of Michigan 
2015 
 
 
 
 
 
 
Doctoral Committee: 
 
           Professor Lori L. Isom, Chair 
           Assistant Professor Justus Mukolu Anumonwo 
           Associate Professor Anatoli N Lopatin  
           Assistant Research Scientist Luis Felix Lopez-Santiago 
           Professor Leslie Satin 
           Professor Héctor Valdivia 
 
 
© Yangyang Bao 2015
ii 
 
ACKNOWLEDGEMENTS 
It is an honor to present the work that I conducted during my PhD training. First, I would 
like to thank Shanghai JiaoTong University and the University of Michigan, as they 
provided me a platform, the MD/PhD joint program, for medical and scientific training. I 
am grateful to all of the students, fellows, faculty, and support staff of the PIBS program 
and Department of Pharmacology. Second, my thesis committee (Drs. Anumonwo, 
Lopatin, Lopez-Santiago, Valdivia, Satin and Isom) has provided valuable guidance in 
my thesis project. Everyone was supportive and helpful in shaping and sharpening my 
knowledge of cardiac electrophysiology.  
Next, all of this work would not have been possible without everything that Dr. Isom has 
offered. She welcomed me into her laboratory and provided world-class scientific 
training. She not only equipped me with solid knowledge but also scientific thinking. Dr. 
Isom taught me how to find the key questions, to figure out a way of testing hypothesis, 
to collaborate with other world-class experts in the field and train my ability to judge my 
peer’s work. Colleagues in her laboratory are kind and knowledgeable, creating a 
suitable atmosphere for me to grow. The journey in her laboratory has been memorable 
and fascinating, exerting impacts on my way of understanding the world into my future 
life. 
iii 
Finally, I owe my gratitude to my parents (Guoguang Bao and Xiaoyan Wu) who have 
stood beside me throughout the entire course of my PhD studies. 
 
  
iv 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS                                                                                                        ii 
LIST OF FIGURES                                                                                                                viii 
LIST OF TABLES                                                                                                                  ix 
LIST OF ABBREVIATIONS                                                                                                   x 
 
CHAPTER 
CHAPTER I ..................................................................................................................... 1 
Introduction: physiology and pathophysiology of voltage-gated sodium channel β 
subunits in the heart. ....................................................................................................... 1 
Introduction .................................................................................................................. 1 
Topology of VGSC α and β subunits ............................................................................ 2 
Localization of VGSC α and β subunits in the heart ..................................................... 3 
Tissue distribution ..................................................................................................... 3 
Subcellular localization ............................................................................................. 4 
VGSCs exist as macromolecular complexes in heart .................................................. 5 
How are cardiac VGSCs modulated in vitro? ............................................................... 6 
Mutations in genes encoding VGSC β subunit are linked to cardiac disease .............. 9 
SCN1B .................................................................................................................... 14 
SCN2B. ................................................................................................................... 17
v 
SCN3B .................................................................................................................... 18 
SCN4B. ................................................................................................................... 21 
Summary ................................................................................................................ 23 
β subunits as accomplices of aberrant NaV1.5. .......................................................... 24 
Additional arrhythmogenic roles of β subunit gene mutations. ................................... 24 
VGSC α subunits other than Nav1.5 are modulated by β subunits in heart. ........... 25 
VGSC β subunits modulate K+ channels. ............................................................... 27 
Roles of β subunits in cardiovascular pharmacology and treatment. ......................... 28 
Summary.................................................................................................................... 29 
CHAPTER II .................................................................................................................. 31 
Scn2b deletion in mice leads to ventricular arrhythmia ................................................. 31 
Introduction ................................................................................................................ 31 
Scn2b deletion results in decreased INa density in ventricular myocytes. ................... 32 
No changes in the distribution of sodium channels recorded from T-tubules or crest 
regions. ...................................................................................................................... 35 
Scn2b null hearts have impaired impulse propagation in the right ventricular outflow 
tract region (RVOT) .................................................................................................... 38 
Scn2b null ventricles are more arrhythmogenic than WT ........................................... 43 
Discussion.................................................................................................................. 49 
Scn2b null mice mimic human Brugada syndrome. ................................................ 49 
PVC and arrhythmogenesis in BrS and Scn2b null hearts ...................................... 50 
CHAPTER III ................................................................................................................. 55 
Conduction system is intact in Scn2b null mice ............................................................. 55 
Introduction ................................................................................................................ 55 
vi 
ECGs from Scn2b null mice suggest bradycardia ...................................................... 56 
Scn2b null mice exhibit a normal cardiac conduction system .................................... 61 
Discussion.................................................................................................................. 64 
Conduction system and autonomic control in Scn2b null mice ............................... 64 
CHAPTER IV ................................................................................................................. 66 
Higher Susceptibility to Atrial Arrhythmia in Scn2b Null Mice ........................................ 66 
Introduction ................................................................................................................ 66 
Scn2b null mice have increased susceptibility to atrial fibrillation in vivo ................... 67 
Re-entry underlies the mechanism of atrial fibrillation in Scn2b null atria .................. 70 
APD is heterogeneously prolonged in Scn2b null atrium ........................................... 76 
Increased fibrosis in Scn2b null right atrium............................................................... 80 
Discussion.................................................................................................................. 83 
AF in BrS ................................................................................................................ 83 
Fibrosis in Scn2b null atria ...................................................................................... 84 
Role of β2 in cellular electrophysiology................................................................... 85 
CHARPTER V ............................................................................................................... 86 
Conclusion and Future Directions ................................................................................. 86 
β2 subunits modulate K+ channels? ........................................................................... 87 
Atrial cardiomyopathy? .............................................................................................. 88 
Role of β2 in the autonomic nervous system? ........................................................... 89 
Large-animal models are a better alternative for arrhythmia studies ......................... 89 
iPSC-CM as cellular models for ion channel mutation study ...................................... 90 
β2: A future therapeutic target for BrS? ..................................................................... 91 
Summary.................................................................................................................... 91 
vii 
CHAPTER VI ................................................................................................................. 93 
Methods ........................................................................................................................ 93 
Animals ...................................................................................................................... 93 
Ethics statement ........................................................................................................ 93 
Cell isolation ............................................................................................................... 93 
Ventricular myocyte isolation for INa recording ........................................................ 93 
Right ventricular outflow track (RVOT) myocyte isolation ....................................... 94 
Isolation of atrial myocytes ..................................................................................... 94 
Single Cell Electrophysiology ..................................................................................... 95 
Voltage Clamp Recordings ..................................................................................... 95 
Current Clamp Recordings ..................................................................................... 96 
Super-resolution scanning patch clamp .................................................................. 96 
Optical Mapping ......................................................................................................... 97 
Ventricular mapping ................................................................................................ 97 
Atrial Mapping ......................................................................................................... 98 
ECG and intracardiac recording ................................................................................. 98 
Assessment of Fibrosis .............................................................................................. 99 
Statistics................................................................................................................... 100 
BIBLIOGRAPHY ......................................................................................................... 101 
 
 
 
viii 
LIST OF FIGURES 
Figure 1 Differential subcellular localization of β1 in rodent ventricular myocytes. .......... 7 
Figure 2 INa recordings from ventricular cardiomyocytes ............................................... 33 
Figure 3 No changes in the distribution of sodium channels recorded from the T-tubules 
or from the crest regions ............................................................................................... 36 
Figure 4 Conduction velocity is decreased in the Scn2b null right ventricular outflow 
tract (RVOT) region ....................................................................................................... 40 
Figure 5 AP recordings from single RVOT myocytes. ................................................... 41 
Figure 6 Arrhythmic events captured in Scn2b null hearts by optical mapping. ............ 45 
Figure 7 Proposed mechanism of VT initiation and rotor formation. .............................. 47 
Figure 8 No differences in PVC coupling interval. ......................................................... 53 
Figure 9 Heart rate was slightly decreased in Scn2b null mice. .................................... 57 
Figure 10 Surface ECG during atrial pacing. ................................................................. 59 
Figure 11 Scn2b null atria are more susceptible to AF. ................................................. 68 
Figure 12 Complex and dynamic rotors underlie the mechanism of AF in Scn2b null 
atria. .............................................................................................................................. 73 
Figure 13 Spontaneous atrial tachyarrhythmia in an ex vivo atrial preparation. ............ 74 
Figure 14 Conduction velocity is not altered in Scn2b null atria. ................................... 77 
Figure 15 AP recordings from right atrial myocytes. ...................................................... 78 
Figure 16 Increased fibrosis in Scn2b null right atrium. ................................................. 81 
 
ix 
LIST OF TABLES 
Table 1 Human Cardiac Arrhythmia-associated VGSC β-Subunit Mutations .................. 9 
Table 2 INa Biophysical Properties ................................................................................. 34 
Table 3 ECG Parameters .............................................................................................. 60 
Table 4 Intracardiac electrophysiological values ........................................................... 62 
 
  
x 
LIST OF ABBREVIATIONS 
WT         Wild type 
EAD       early afterdepolarization 
PVC       premature ventricular complex 
AP         action potential 
APD       action potential duration 
RVOT    right ventricular outflow tract 
DF         dominant frequency  
AF         atrial fibrillation  
BrS        Brugada syndrome 
AF/AT    atrial fibrillation/atrial tachyarrhythmia  
RV         right ventricle  
LV         left ventricle 
ECG      electrocardiogram  
HR         heart rate 
AERP    atrial effective refractory period
 1 
CHAPTER I 
Introduction: physiology and pathophysiology of voltage-gated sodium channel β 
subunits in the heart. 
 
Previously published as Bao Y and Isom LL. NaV1.5 and Regulatory β Subunits in 
Cardiac Sodium Channelopathies. Card Electrophysiol Clin. 2014;6(4):679–694.  
 
Introduction   
Voltage-gated sodium channels (VGSCs) are critical for impulse initiation and 
propagation in excitable cells, including nerve and muscle. The ion-conducting VGSC α 
subunits are modulated by two β subunits that do not form the pore but play essential 
roles in electrical signal transduction. VGSC β subunits signal through multiple 
pathways on multiple time scales in vivo and, at least for β1, are essential for life. In 
addition to regulating sodium current, β subunits associate with potassium channels and 
play non-conducting roles as cell adhesion molecules (CAMs) that participate in cell-cell 
coupling and macromolecular complex formation. Mutations in genes encoding VGSC β 
subunits disrupt both sodium and potassium channel complexes as well as cell-cell 
communication, leading to heart and brain diseases that can be catastrophic. In this 
chapter, I will begin with a discussion of β subunit tissue distribution and subcellular 
localization in the heart, laying the groundwork for a discussion of the anatomical basis 
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of β subunit-linked cardiac disease. I will provide an overview of β subunit 
electrophysiological function in vitro and in vivo in heart and discuss cardiac disease-
related β subunit gene mutations, clinical phenotypes, and their implications. Possible 
mechanisms of β subunit-mediated cardiac arrhythmias will be presented. The 
pathophysiological implications of simultaneous expression of β subunit gene mutations 
in heart and brain will be considered. 
 
Topology of VGSC α and β subunits 
VGSCs are responsible for the upstroke of the cardiac action potential (AP) and are 
required for impulse propagation in the heart1. Structurally, three different subunits are 
required to assemble the VGSC complex in brain: one pore-forming α subunit that is 
both covalently and non-covalently linked to two different β subunits2. Because cardiac 
VGSCs have not been purified, it is assumed, but not proven, that they are also 
heterotrimers. Five β subunit proteins have been identified in mammals, including β1, 
β1B, β2, β3 and β4. They are encoded by four genes: SCN1B-SCN4B3–7. While the 
pore forming VGSC α subunit is sufficient for ion conduction, at least in heterologous 
systems, β subunits regulate sodium current (INa) density, kinetics, voltage-dependence 
of activation and inactivation as well as surface expression. In addition to INa 
modification, β subunits also function as cell adhesion molecules (CAMs)8, mediating 
cellular aggregation, neuronal migration, pathfinding, and axonal fasciculation in brain9. 
While our knowledge of β subunit-mediated cell-cell adhesion in heart is not as 
extensive, we propose that β subunits contribute to cell-cell coupling at the intercalated 
disk (ID)10. With the exception of β1B, all of the VGSC β subunits share similar 
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topologies, containing a single, heavily glycosylated, immunoglobulin (Ig) fold in the 
extracellular region, a single transmembrane domain, and an intracellular C-terminus7. 
β1B (originally called β1A4), a SCN1B splice variant formed through retention of intron 3, 
contains an Ig loop that is identical to that of β1, but lacks a transmembrane domain and 
is thus a secreted protein11. β1B functions as a soluble CAM ligand in addition to a 
modulator of INa 11. Of the five β subunits, β1B, β1, and β3 are non-covalently linked to 
VGSC α subunits, while β2 and β4 are covalently linked through disulfide bonds. The 
residue responsible for the covalent interaction between β2 and α subunit was recently 
identified as cysteine-2612. β4, which shares several similar cysteine sites with β2, is 
postulated to link to VGSC α subunits through cysteine-285. 
 
Localization of VGSC α and β subunits in the heart 
Tissue distribution  
Importantly, and similar to cardiac potassium channels13,14, VGSC α and β 
subunits exhibit gradients of expression throughout the heart. All β subunits, 
except for β1B, are expressed in mouse sinoatrial (SA) node 15. The 
predominant cardiac VGSC α subunit, NaV1.5, is absent from the central 
region of the SA node but its expression increases in a gradient fashion 
toward the peripheral SA nodal region16.  This arrangement is proposed to 
play a key role in controlling impulse exit from the node17. The TTX-sensitive 
(TTX-S) VGSCs NaV1.1 and NaV1.3 are expressed in the central SA node, 
with NaV1.1 as the predominant sodium channel in this region. In mouse heart, 
the SA and atrioventricular (AV) nodal regions have higher expression levels 
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of SCN1B (encoding β1/ β1B) and SCN3B (encoding β3) compared to the 
atrium18. SCN1A (encoding NaV1.1) and SCN9A (encoding NaV1.7) are also 
highly expressed in AV node18. Profiling of ion channel genes in non-diseased 
human heart revealed that SCN5A (encoding NaV1.5) and SCN9A transcript 
levels are higher in left atrium than left ventricle, while SCN1B is expressed at 
a higher level in both left and right atria compared to the two ventricles19. 
SCN3A (encoding NaV1.3) is expressed at lower levels in right atrium than 
right ventricle. Interestingly, the TTX-S VGSC SCN9A, which is more often 
expressed in neurons, is more highly expressed in “neuronal-like” Purkinje 
fibers compared to right ventricle. Both SCN5A and SCN1B transcript levels 
are higher in endocardium than in epicardium. Nevertheless, SCN2B 
(encoding β2) and SCN3B appear to be homogeneously distributed 
throughout the heart19. In contrast to findings in human heart, SCN3B is 
highly expressed in the ventricles and Purkinje fibers but not in the atria in 
sheep heart20. β1 expression is higher in the trabeculated myocardium and 
the bundle branches in postnatal mouse21.  Taken together, it is clear that a 
detailed understanding of VGSC subunit localization is critical to 
understanding the mechanisms of cardiac physiology and pathophysiology. 
 
Subcellular localization 
Both TTX-S and TTX-R VGSCs are expressed in cardiac myocytes. TTX-R 
NaV1.5 co-localizes with tyrosine phosphorylated β1, β2, and β4 at the ID, 
while non-phosphorylated β1, β2, and β3 co-localize with TTX-S NaV1.1, 
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NaV1.3 and NaV1.6 at the transverse-tubules (T-tubules) in rodent ventricular 
myocytes10,22,23. A recent study also revealed low-level cell surface 
expression of NaV1.4 and NaV1.6 in mouse ventricular myocytes24. In human 
atrial myocytes, NaV1.2 is co-localized at IDs with β1 and β3. NaV1.4 and the 
predominant NaV1.5 channels are co-localized with β2 in a striated pattern. 
NaV1.1, NaV1.3, and NaV1.6 are located in scattered puncta on the cell 
surface in a pattern similar to β3 and β425. Because the subcellular 
distributions of VGSC α and β subunits in human heart appear to be different 
than in mouse and rat, a more complete study using reliable antibodies will be 
an important next step in our pursuit of novel therapeutic agents to treat 
cardiac disease in human patients.  
 
VGSCs exist as macromolecular complexes in heart 
Mammalian VGSCs exist as macromolecular complexes in vivo. Immunoprecipitation 
studies showed that NaV1.5, β1, and β2 associate in solubilized rat heart membranes22. 
Phosphorylated β1 (at residue tyrosine-181) co-localizes with connexin-43, N-cadherin, 
and NaV1.5 at rodent IDs but is not detected at the t-tubules10. Co-immunoprecipitation 
demonstrated that N-cadherin, an adherens junction protein, interacts with 
phosphorylated β1 in rodent heart membranes as well as in a heterologous system via 
the β1 extracellular domain. Connexin-43, a gap junction protein that is critical for 
impulse propagation, associates with the NaV1.5 complex in heart membranes10. The 
cytoskeletal adaptor protein, ankyrin, is a member of the VGSC signaling complex in 
heart26. AnkyrinG (AnkG), which interacts directly with NaV1.5 at the ID, is required for 
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NaV1.5 targeting, expression, and biophysical function27. Disruption of AnkG-NaV1.5 
interactions is associated with Brugada syndrome (BrS)28.   Plakophilin-2 (a 
desmosomal protein) interacts with connexin-43, and AnkG at the ID29. Thus, 
desmosomes, gap junctions, and VGSC α and β subunits constitute an interacting 
network, or “connexome”, at the ID, controlling excitability, electrical coupling, and 
intercellular adhesion in the heart30. At T-tubules, another ankyrin isoform, ankyrinB 
(AnkB) co-assembles with TTX-S VGSCs by binding to the non-phosphorylated C-
terminal region of β110. Mutations in ANK2, encoding AnkB, result in ankyrin-B 
syndrome (formerly LQT4) with a wide spectrum of phenotypes31,32. Interestingly, 
interactions between β1 and ankyrin are abolished in a heterologous system by 
expression of a β1 construct that mimics phosphorylated β1 (β1Y181E), suggesting that 
β1 tyrosine phosphorylation is important for ankyrin recruitment and thus VGSC 
complex formation in heart33.  These interactions are summarized in Figure 1. 
 
How are cardiac VGSCs modulated in vitro?  
A conventional method to study ion channels and mutant channels linked to 
channelopathies is functional expression in heterologous systems. Although far from the 
native environment, in vitro studies are a convenient first approach to gain structure-
function information. Co-expression of β subunits with the predominant cardiac VGSC 
NaV1.5 in heterologous systems has yielded valuable but also confusing information. 
β1-mediated effects on NaV1.5 are inconsistent between laboratories. Some groups 
report no effect of β1 on NaV1.5 function34,35. Others report that β1 increases NaV1.5 INa  
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Figure 1 Differential subcellular localization of β1 in rodent ventricular myocytes.  
The TTX-R VGSC NaV1.5 co-localizes with ankyrinG, tyrosine-phosphorylated β1, in 
close association with both N-cadherin and connexin-43, at intercalated disks in 
ventricular myocytes10.  Non-phosphorylated β1 and ankyrinB co-localize with the TTX-S 
VGSCs NaV1.1, NaV1.3, and NaV1.6 at the t-tubules10,23. Although both β1 and β1B 
have been demonstrated to modulate Ito, their spatial relationship to the KV4.x/KChiP2 
complex is unknown36–38. β2 has been detected at intercalated disks23 and T-tubules22 
by immunostainings. β3 and β4 are preferentially expressed  at T-tubules and 
intercalated disks respectively23. According to cardiac sodium channel “multiple pool” 
model39, NaV1.5 is also localized at lateral membrane. Besides, low level of NaV1.4 and 
NaV1.6 are also detected on cell surface24. The β subunit isoform has not been 
identified and will be an interesting topic for future study.  
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density without affecting the gating properties40, that β1 shifts the voltage dependence 
of inactivation22,41,42, or that β1 alters the rate of recovery from inactivation20,42. This 
variety of results may stem from differences in cell background, endogenous β subunits, 
or differential expression of channel interacting proteins43–46. Surprisingly, we found that 
NaV1.5 retains β1B, the secreted splice variant of Scn1b, at the cell surface in 
heterologous cells11. β1B co-expression results in increased NaV1.5-mediated INa 
density and a hyperpolarized shift in the voltage-dependence of gating47. In contrast, β2 
co-expression seems to consistently have no effect on NaV1.5 mediated INa density, 
kinetics, or gating properties in vitro12,22,48. In Xenopus oocytes, a system in which INa is 
considered to be non-physiological, β3 increases Nav1.5 INa density, shifts the voltage 
dependence of inactivation in the depolarizing direction, and increases the rate of 
recovery from inactivation20.  In Chinese hamster ovary-K1 cells, β3 has no effect on 
Nav1.5 peak INa but reduces persistent INa, shifts the voltage dependence of inactivation 
in the hyperpolarizing direction, and decelerates the rate of recovery from inactivation42. 
β4, containing a sequence in its intracellular domain (ICD) that causes open channel 
block, is unique among VGSC β subunits because of its capability of resurgent INa 
generation49 (although Scn1b null mice show reduced resurgent INa current in the 
cerebellum, also implicating β1/ β1B in this mechanism50). β4-mediated resurgent INa 
can be recapitulated with NaV1.5 in vitro51. Compared to NaV1.5 alone, β4 co-
expression decreases the slope of both the voltage-dependence of activation and 
inactivation52 with a hyperpolarizing shift in inactivation53, and accelerates recovery from 
inactivation in HEK293 cells52.  
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Taken together, the large variability in functional results obtained for β subunit 
expression in heterologous systems calls for carefully controlled comparisons of subunit 
combinations and functions of disease-related mutations with WT controls in the same 
cell line under the same recording conditions. Better yet, it is critical to move beyond 
heterologous expression systems and “ask the animal,” so to speak, using transgenic 
models to investigate the functions of these important proteins in vivo. 
 
Mutations in genes encoding VGSC β subunit are linked to cardiac disease 
Table 1Table 1 Human Cardiac Arrhythmia-associated VGSC β-Subunit 
Mutations 
Gene Affected 
isoform  
Model  Location Affected 
AA 
Mutation MAF 
(%)a 
Disease Functional 
Alteration 
(Ref) 
SCN1B β1, β1b  
 
 
 
 
 
 
Human 
 
ECD R85H c.254G>A NA AF or 
GEFS+ 
Reduced 
INa, and 
altered 
gating 
(CHO)48  
β1, β1b ECD E87Q c.259G>C NA CCD Reduced 
INa, altered 
gating  
(CHO) 47 
β1, β1b ECD D153N c.457G>A NA AF Reduced 
INa, 
(CHO)48  
β1, β1b ECD V138I c.412G>A 0.0231 SUNDS NA54 
β1 TMD T189M c.583G>A NA SUNDS NA54 
β1b  W179X 
 
c.537G>A 
c.536G>A 
NA CCD,  
BrS & 
CCD 
Reduced 
INa and 
altered 
gating 
(CHO) 47 
 
β1b 
 
  
R214Q 
 
 
c.641G>A 
 
 
0.3306 
 
BrS, 
SIDS, AF 
Reduced 
INa,, 
Slower 
recovery 
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from 
inactivation
; Increased 
Ito 
decelerated 
Ito decay 
(tsA 
201)36,55 
 
β1b 
 
  
H162P 
 
c.641G>A 
 
NA 
 
BrS 
Reduced 
INa Altered 
gating; 
slower 
recovery 
from 
inactivation 
(CHO-K1)56 
β1, β1b Mouse  Null   LQT Increased 
INa peak & INa 
persistent, 
increased 
APD57 
SCN2B  
 
β2 
 
 
 
Human 
SP R28W c.82C>T 0.0077 AF  Reduced 
INa, and 
altered 
gating 
(CHO)48  
SP R28Q c.83G>A NA AF Reduced 
INa and 
altered 
gating 
(CHO)48  
ICD D211G c.632A>G NA BrS Reduced 
INa (CHO), 
decreased 
surface 
expression
58 
SCN3B 
 
 
 
 
  
 
 
 
 
 
 
 
β3 
 
 
 
 
 
 
 
 
 
Human 
SP R6K c.17G>A NA AF Altered 
gating of 
INa (CHO-
Pro5)59  
 
SP 
 
L10P 
 
c.29T>C 
 
0.0077 
 
BrS, AF 
Reduced 
INa, altered 
gating, 
and 
trafficking 
defect 
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(tsA201, 
CHO-
Pro5)59,60  
ECD V36M c.106G>A NA SIDS Reduced 
INa,peak, 
increased 
INa,persistent 
(HEK293)53  
 
ECD 
 
V54G 
 
c.161A>C 
 
NA 
 
SIDS, IVF 
Reduced 
INa, altered 
gating , 
and 
trafficking 
defect 
(CHO, 
HEK293)53,
61  
ECG A130V c.389C>T NA AF Reduced 
INa 
(HEK293)62 
TMD M161T c.482T>C NA AF Reduced 
INa (CHO-
Pro5)59  
ECM V110I c.328G>A 0.0385 BrS Reduced 
INa, 
trafficking 
defect 
(tsA201)71  
ICD A195T c.583G>A 0.0077 SUNDS NA54 
Mouse  Null   BrS & 
Sinus 
dysfunct
ion 
Reduced 
INa and 
altered 
gating63,64 
SCN4B  
 
 
β4 
 
 
 
Human 
TMD L179F c.535C>T NA LQT & 
AVB 
Altered 
gating of 
INa, 
increased 
INa, 
persistent 
(HEK293)48  
 
ICD 
 
S206L 
 
c.617G>A 
 
0.0154 
 
SIDS 
Increased 
INa persistent 
(HEK293 
and 
myocytes), 
increased 
APD 
 12 
(myocytes
)53  
TMD V162G c.485T>G NA AF NA65 
TMD I166L c.496A>C NA AF NA65 
 
ECD: extracellular domain; TMD: transmembrane domain; ICD: intracellular domain; SP: signal peptide; 
AF: atrial fibrillation; GEFS+: Genetic Epilepsy with Febrile Seizure Plus; BrS; Brugada Syndrome; SIDS: 
Sudden Infant Death Syndrome; LQT: Long QT Syndrome; CCD: Cardiac Conduction Disease; AVB: 
Atrial-Ventricular Block; SUNDS: Sudden Unexpected Nocturnal Death Syndrome; MAF: Minor Allele 
Frequency (listed frequency is the frequency in all populations including European American and African 
American) based on NHLBI GO Exome Sequencing Project (http://evs.gs.washington.edu/EVS/).   
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Human mutations in SCN5A underlie a number of cardiac disorders ranging from 
arrhythmias to cardiomyopathies. Because β subunits modulate NaV1.5 in vitro (at least 
in some hands), mutations in the genes encoding these subunits were predicted to be 
associated with a similar spectrum of cardiac diseases. Numerous candidate gene 
association studies were performed in cohorts of patients with cardiac arrhythmias who 
were negative for SCN5A mutations. Since 2007, a number of mutations in SCN1B-
SCN4B have been associated with arrhythmias of various etiologies. Table 1 
summarizes these results. These can be generally characterized either as resulting in 
NaV1.5 gain- or loss-of-function. β subunit gene mutations resulting in NaV1.5 gain-of-
function are linked to long QT syndrome (LQTS)52 and sudden infant death syndrome 
(SIDS)53. β subunit gene mutations resulting in NaV1.5 loss-of-function are linked to 
BrS47, progressive cardiac conduction disease (CCD)47, atrial fibrillation (AF)48, and 
idiopathic ventricular fibrillation (IVF)61. In addition, homozygous SCN1B loss of function 
mutations are linked to Dravet Syndrome (DS), a severe pediatric epileptic 
encephalopathy with a high risk of Sudden Unexpected Death in Epilepsy or 
SUDEP66,67.  We and others have proposed that the expression of SCN1B mutations in 
brain and heart may result in epilepsy and cardiac arrhythmias, setting up a “perfect 
storm,” so to speak, with a sometimes fatal result57,68. 
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SCN1B  
Ventricular arrhythmias and cardiac conduction system defects 
The first cardiac disease mutations identified in SCN1B were associated with BrS 
(BRGDA5 OMIM 612838) and cardiac conduction defects (OMIM 612838)47. In this 
study, 282 BrS and 44 cardiac conduction disease patients were screened. A missense 
mutation in SCN1B, p.Glu87Gln, predicted to affect both β1 and β1B, was reported in a 
BrS patient who also manifested conduction abnormalities. These authors also reported 
a nonsense mutation, predicted to result in truncation of β1B at residue 179, in two 
bundle branch block patients. Channel function tests performed in a heterologous 
system co-expressing NaV1.5 with WT vs. mutant β1 or β1B showed that mutations 
reduce INa density. In addition, p.Glu87Gln decreases channel availability by shifting the 
voltage dependence of inactivation in the hyperpolarizing direction. In 2011, a novel 
variant of β1B, p.R214Q, was described in both BrS and SIDS36. This mutation 
decreases INa density by 56.5% and decelerates the rate of recovery from inactivation, 
resulting in loss of NaV1.5 function in a heterologous system. Interestingly, this mutation 
also increases transient outward potassium current (Ito) by 70.6% in tsA201 cells, 
resulting in a gain of Kv4.3 (KCND3) channel function. This was the first time that a 
functional association between β1B and Kv4.3 was demonstrated. These findings 
extend the mechanistic roles of β subunits in arrhythmogenesis and reinforce the 
mechanism proposed for BrS. It is clear that INa reduction plays a pivotal role in causing 
BrS 69. The repolarization and depolarization hypotheses are two proposed mechanisms, 
each involving reduced INa, underlying BrS that are supported by experimental and 
clinical data70.  In brief, in the repolarizing hypothesis, AP durations are shorter in the 
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epicardium, attributed to the more prominent expression of repolarizing Ito. Reduction in 
“opposing” or depolarizing INa would further shorten epicardial AP durations, resulting in 
higher heterogeneity of transmural voltage gradients between the right ventricular 
epicardium and endocardium. Thus, reentrant excitation waves (Phase 2 reentry) 
between depolarized endocardium and prematurely repolarized epicardium may be 
facilitated. In the depolarization hypothesis, right ventricular outflow tract activation 
delay due to preferential conduction slowing would be aggravated by INa reduction, 
which could trigger the occurrence of epicardial reentry.  In addition to INa reduction, 
β1B p.R214Q may cause further augmentation of the transmural voltage gradient due to 
increased Ito. Since both β1 and β1B transcript expression levels are higher in the right 
vs left ventricle47, SCN1B tissue distribution may confer preferential conduction slowing 
in the right ventricle when defects occur. Thus, the pathogenesis proposed to be 
associated with β1B p.R214Q fits both hypotheses underlying BrS. This same mutation 
was later identified in one BrS patient and two early-onset lone AF patients from a 
different cohort collected in Denmark55. Both AF patients presented with incomplete 
right bundle branch block and a downslope ST segment, suggesting a phenotypic 
overlap between this SCN1B mutation and SCN5A loss-of-function mutation related 
arrhythmias. To discriminate true monogenetic disease-causing variants from low-
frequency genetic variants, the β subunit genes SCN1B through SCN4B were screened 
for variations in a population of SCN5A mutation negative Danish and Iranian BrS 
patients.  This group also re-investigated prior associations using newly released exome 
data. They identified a new SCN1B mutation in β1B, p.H162, which was not present in 
controls or public databases. However, they also identified p.R214Q in the general 
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population with 0.4% minor allele frequency (MAF), thus raising doubts about p.R214Q  
as a causative mutation71. Subsequent to these studies, SCN1B p.V138I and p.T189M 
were found to be linked to sudden unexplained nocturnal death syndrome (SUNDS)54. 
Interestingly, SUNDS and BrS are considered by some investigators to be 
phenotypically similar72.    
 
Atrial arrhythmias.  
Defects in SCN5A leading to loss of INa are involved in the pathogenesis of familial 
AF73,74. Not surprisingly, the same is true for SCN1B. In addition to SCN1B p.R214Q 
described above, SCN1B p.R85H and p.D153N are associated with familial AF (ATFB 
13 OMIM 615377). SCN1B p.R85H, located in the Ig loop region, affects both β1 and 
β1B.  In contrast, p.D153N is located in exon 4 of SCN1B and thus can only affect β1. 
Both mutations result in INa reduction in heterologous expression systems. In addition, 
p.R85H, which has also been described in a patient with epilepsy75, shifts both the 
voltage dependence of activation and inactivation positively. Decreased INa density may 
shorten the refractory period and reduce conduction velocity, creating a substrate for re-
entry initiation and perpetuation and thereby contributing to AF susceptibility76.  
 
Animal models of SCN1B mutations.  
All of the human patients thus far described with SCN1B-linked cardiac disease are 
heterozygotes. In contrast, epilepsy patients have been identified with both 
heterozygous and homozygous mutations66,67, suggesting that homozygous SCN1B 
patients with cardiac disease may also be identified. The majority of these mutations are 
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located in the extracellular Ig domain, emphasizing the importance of this domain in 
current modulation and supporting the hypothesis that SCN1B-mediated cell-cell 
adhesion is clinically relevant77. To study the physiological roles of SCN1B in the heart, 
we generated Scn1b null mice and studied their cardiac phenotype 57,68. Scn1b null 
mice are models of DS and exhibit severe seizures and SUDEP68,77. Interestingly, and 
consistent with patients with SCN1B mutations that affect the heart, we observed both 
bradycardia and a prolonged QT interval, suggesting VGSC gain-of-function. Indeed, 
we found a 1.6-fold increase in both peak and persistent INa density as well as increased 
AP duration in ventricular cardiac myocytes. These electrophysiological changes could 
be explained by increases in transcript and protein levels of Scn5a and NaV1.5, 
respectively. Although Scn1b+/- mice are closer to the situation in human patients with 
heterozygous loss-of-function SCN1B mutations, the cardiac phenotype of these mice is 
unremarkable. The reason why the Scn1b+/- model fails to recapitulate clinical findings 
in humans is unknown, although genetic background differences may play a role. 
Moreover, the atrial phenotype of Scn1b null mice has not yet been described. To 
further separate the role of β1 from β1B in the heart, reintroduction of one splice variant 
at a time into the Scn1b null mice remains under investigation.  
 
SCN2B.  
Only three missense mutations have been identified in SCN2B to date, two of which 
result in amino acid substitution at residue 28 in the β2 signal peptide domain, p.R28W 
and R28Q, as reported in 2009. Both result in loss-of-function in a heterologous system 
and are linked to paroxysmal AF in human patients. Both AF patients, who were 
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heterozygous for these mutations, demonstrated saddleback-type ST segment elevation 
in the right precordial leads and one patient had PR interval prolongation (220ms)48. 
Thus, a BrS like phenotype and conduction abnormalities may be concomitant with an 
atrial phenotype in a single AF patient. β2 p.D211G, located in the ICD, was discovered 
in 2013 associated with BrS. This mutation results in reduced NaV1.5 cell surface 
expression, without affecting single channel conductance, in heterologous cells58. 
Interestingly β2, similar to amyloid precursor protein, can be sequentially cleaved by β 
and γ secretases78. The cleaved ICD of β2 translocates to the nucleus to modulate 
Scn1a transcription in neurons79. Although we do not know whether the β2 ICD also 
exerts transcriptional modulation on SCN5A in cardiomyocytes, this might be an 
alternative explanation for reduced surface expression.  
 
SCN3B 
Ventricular arrhythmia.  
The first mutation in SCN3B, p.L10P, was linked to BrS (BRGDA7 OMIM 613120)60.  
Heterologous expression showed an 82.6% decrease in peak INa density, an 
accelerated rate of inactivation, a slowed recovery from inactivation, and a negative 
9.6mV shift in the voltage dependence of inactivation. Immunofluorescence revealed 
that NaV1.5 remained trapped in intracellular organelles when co-expressed with WT 
SCN1B and mutant SCN3B p.L10P. Similarly, β3 p.V110I, another trafficking mutation, 
was found in three Japanese BrS patients from a cohort of 181 individuals80.  Due to the 
relative high prevalence of β3 p.V110I in SCN5A mutation-negative Japanese BrS 
patients (10.5% familial cases and 0.6% sporadic cases), a decision was made to begin 
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testing for SCN3B mutations in the Japanese population81.  Another β3 trafficking 
mutation, p.V54G, was identified in IVF61 and SIDS53. This mutation did not disrupt the 
association between α and mutant β subunits, but shifted the voltage dependence of 
channel gating towards more positive potentials. In the case of IVF, the patient was a 
20-year-old male whose positive baseline ECG finding was limited only to epsilon 
waves, which is often a characteristic manifestation of arrhythmogenic right ventricular 
dysplasia (ARVD)82. However, the T waves were not inverted in the right precordial 
leads, and there was no other evidence to suggest ARVD. While neither SCN5A nor β 
subunit genes have been implicated in ARVD, a disease more likely caused by defects 
in desmosomal genes 83,84, VGSCs have been implicated in the connexome and their 
dysfunction may harm the integrity of this multimolecular complex. Therefore, VGSC 
subunit mutations may share some clinical features of ARVD30. Thus, if a patient 
presents with ARVD-like symptoms but without mutations in the usual ARVD-linked 
desmosomal genes, VGSC genes might be good candidates for screening.  Finally, β3 
p.A195T was detected in a 31-year-old SUNDS patient, although functional studies 
were not reported.  
 
Atrial arrhythmias  
β3 p.A130V was reported in 2010 in a candidate gene association study in a cohort of 
477 Chinese AF patients. This mutation results in decreased INa density and acts as a 
dominant negative in the presence of WT β3. Interestingly, however, surface 
biotinylation experiments revealed no changes in cell surface expression level of 
NaV1.562. Single channel recording of unitary conductance would have been helpful to 
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further elucidate the INa reduction mechanism. Later, to increase the probability of 
screen hits, a cohort was tested with more restricted inclusion criteria in which only 
early-onset (younger than age of 40) lone AF patients were included59. Three mutations, 
β3 p.R6K, p.L10P, and p.M161T, were identified. β3 p.L10P co-expression with NaV1.5 
and WT β1 results in a 45% decrease in peak INa and a 3.8mV negative shift of voltage 
dependence of inactivation compared to NaV1.5 co-expressed with WT β1 and β3. 
p.M161T causes a 57% decrease in peak INa without observable changes in the voltage 
dependence of gating. In contrast, p.R6K only shifts the voltage dependence of 
inactivation by 5mV in the hyperpolarizing direction. Both p.R6K and p.L10P are located 
in the signal peptide region of β3 while p.M161T is at the border of the transmembrane 
domain. p.L10P was previously identified in BrS 60and was shown to interrupt protein 
trafficking. Overall, additional in vivo work will be required to understand the 
mechanisms of these mutations. 
 
Animal models of SCN3B.  
Monomorphic VT can be induced in Scn3b null mice, using programmed electrical 
stimulation, that degenerated to polymorphic VT, suggesting that the ventricles in these 
animals are prone to arrhythmia63. This idea is supported by additional findings, 
including conduction abnormalities, shorter ventricular effective refractory periods, and a 
reduction in INa despite an increase in the expression levels of Scn5a mRNA in the right 
ventricle. The similarity of these electrophysiological features to clinical BrS suggest that 
Scn3b null mice may serve as a BrS model63. Shortly after their initial publication, the 
same group also reported bradycardia, increased P wave duration, prolonged PR 
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interval, and complete AV block in Scn3b null mice, demonstrating electrical 
abnormalities in the cardiac conduction system and atria. In addition, they found 
increased SA node recovery times and inducibility of atrial tachycardia and AF by burst 
pacing, extending the potential use of these animals as models for sick sinus syndrome 
(SSS) or AF.64 Interestingly, in contrast to Scn1b null mice, no neurological phenotypes 
were reported, suggesting that the most important functional roles of Scn3b may be in 
the heart. A recent study resolved the crystal structure of the β3 Ig domain, revealing 
that is assembles as a trimer in the crystal asymmetric unit. Using fluorescence 
photoactivated localization microscopy, these authors detected full length β3 trimers on 
the plasma membrane of transfected HEK293 cells85. Interestingly, β3 subunits are 
shown to bind to more than one site on NaV1.5 and induce the formation of α subunit 
oligomers including trimers. Thus, these results suggest that β3 may participate in cell 
adhesion via cis-homophilic interactions, despite a controversy in the literature 
regarding the ability of β3 to mediate trans-homophilic cell adhesion86,87.  Furthermore, 
mutations that perturb the formation of channel trimers are proposed to contribute to 
arrhythmia 85.     
 
SCN4B.  
So far, of the four VGSC β subunit genes, only SCN4B is linked to LQTS (LQT10, 
OMIM 611819)52. In addition, SCN4B is the only β subunit gene with a mutation that 
shows complete penetrance in an AF affected family65. Similar to SCN3B, SCN4B is 
linked to SIDS53.  β4 p.L179F, identified in a LQTS patient, does not alter INa density or 
channel kinetics. Instead, it increases window current through a positive shift in the 
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voltage dependence of inactivation, widening the voltage range in which INa may 
reactivate88.  More importantly, β4 p.L179F causes a dramatic 8-fold increase in 
persistent INa at -60mV. Increased persistent INa prolongs the AP duration. The resulting 
delay in repolarization triggers early afterdepolarizations (EADs), which are proposed to 
induce torsades de pointes89. Notably, this LQTS patient also exhibited asymptomatic 
bradycardia and 2:1 AV block. Intermittent functional 2:1 AV block in the setting of 
LQTS is usually an isolated disorder90 with poor prognosis91. Based on these data, 
direct and independent pathological roles of β4 in 2:1 AV block in patients with LQTS 
were suspected52. Although SCN4B is not yet associated with conduction disease in 
humans, Scn4b is a genetic modifier of disease severity of cardiac conduction defects in 
mice92. Accordingly, SCN4B variants may be considered in risk stratification in LQTS 
patients. Similar to β4 p.L179F, another gain-of-function mutation, β4 p.S206L identified 
in SIDS, does not affect peak INa, but shifts inactivation positively by 7mV, and 
increases both window current and persistent INa. To more closely mimic the native 
environment, functional assays were carried out in rat cardiomyocytes infected with 
adenovirus53.  Due to the close proximity of p.S206 to the β4 open-channel blocking 
sequence, it was postulated that the mutation may enhance the degree of resurgent 
current. Resurgent INa -specific protocols in whole-cell patch clamp recordings will be 
necessary to test this hypothesis. In 2013, two transmembrane domain mutations in β4, 
p.V162G and p.I166L, were detected in two AF affected Chinese families65. Linkage 
analysis revealed complete penetrance in both pedigrees, although INa modulation was 
not tested. Interestingly, in one p.V162G family member, LQTS was also diagnosed, 
implying gain-of-function. No mutations related to arrhythmia have yet been found in the 
 23 
extracellular domain of β4, suggesting that, rather than the extracellular Ig loop domain 
functions being clinically relevant as in β1, malfunction in β4 may be more associated 
with the transmembrane and intracellular domains. The recent crystallization of the β4 
extracellular domain, however, may shed new light on the pathophysiological relevance 
of this region93. 
 
Summary  
The penetrance of VGSC β subunit gene mutations in human patients is variable. Not 
all carriers develop arrhythmia and individuals with the same mutation may develop 
different clinical phenotypes that include epilepsy in addition to cardiac disease75. Low 
penetrance and variable expressivity may stem from epigenetic factors, age, gender, or 
genetic modifiers. Sporadic occurrence without familial co-segregation and the rarity of 
these genetic diseases add complexity to understanding the role of mutant VGSC β 
subunits in arrhythmogenesis. Conclusions of causality have become more difficult to 
draw in contrast to the rapid growth of genetic information from cohorts of cardiac 
patients. A practical process of determining potential disease-causing mutations, 
proposed by Møller et al, is recommended here94. Regardless of the genetic information, 
however, there is no substitution for expression studies, especially the generation of 
transgenic animal models.  That said, the cost in time and resources required to perform 
these experiments necessitate the careful selection of variants to be studied. 
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β subunits as accomplices of aberrant NaV1.5.   
β subunits are not innocent bystanders in SCN5A-linked cardiac disease.  Instead, they 
can modify disease severity and, in some cases, their expression is required for 
pathogenesis. For example, the SCN5A LQT mutation, p.D1790G, results in 
abolishment of α-β1 association and subsequent loss of channel modulation by β195.  
Functional defects of the BrS-related SCN5A mutation p.T1620M are aggravated by co-
expression of β196. In another example, reduced expression of β4 in hearts of 
transgenic mice carrying the BrS- and CCD-related Scn5a-1798insD mutation 
correlates with more severe conduction abnormalities92. In a study investigating the 
mechanism of a BrS-associated trafficking defective mutation, SCN5A p.R1432G, a 
dominant negative effect could be achieved 
only in the presence of β197, suggesting that β1 is required for mutant-WT NaV1.5 
association. In sum, β subunits are actively involved in modulating the severity of 
SCN5A-linked cardiac diseases.  
 
Additional arrhythmogenic roles of β subunit gene mutations.  
Thus far we have characterized cardiac β subunit gene mutations relative to their effects 
on NaV1.5 function. However, these mutations may not contribute to cardiac 
pathogenesis solely through modulation of NaV1.5. β subunits also associate with and 
modulate TTX-S VGSCs and K+ channels in heart10,37. As CAMs, β subunits, especially 
β1, function in cell-cell coupling and serve as adaptor proteins that link cytoskeletal, 
signaling, and other adhesion molecules to macromolecular ion channel complexes10.  
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Thus, β subunit gene mutations can disrupt more than NaV1.5 function to cause cardiac 
disease.  
 
VGSC α subunits other than Nav1.5 are modulated by β subunits in heart.  
Besides NaV1.5, other VGSCs are expressed in the heart and are modulated by β 
subunits, contributing to the maintenance of normal cardiac function. TTX-S VGSCs in 
SA node are important contributors to cardiac automaticity. In isolated SA node cells, 
TTX-S INa initiates during the late phase of the pacemaker potential. Blockade of TTX-S 
INa results in slowed pacemaking in both intact SA node preparations and isolated SA 
node cells16. Similarly, upon perfusion of nanomolar concentrations of TTX into the 
intact isolated mouse heart, a significant reduction in spontaneous heart rate and 
markedly greater heart rate variability are observed, similar to SSS in humans15. In a 
volume-overloaded heart failure (HF) rat model, down-regulation of TTX-S NaV1.1 and 
NaV1.6 expression contributes to HF-induced SA node dysfunction98. TTX-S VGSCs in 
T-tubules of ventricular myocytes play an important role in coupling depolarization of the 
cell membrane to contraction. Low TTX concentrations reduce left ventricular function99. 
This important role was also confirmed in the rabbit100.  To understand the role of one of 
the TTX-S VGSCs in heart, the cardiac phenotype of global Scn8a null mice was 
characterized. Both the PR and QRS intervals were prolonged in this model and Ca2+ 
transients were longer in isolated null myocytes compared to controls. Optical mapping 
showed that hyperkalemia exaggerates the slowing of conduction velocity in Scn8a null 
mouse hearts, implying that NaV1.6 may serve as a protective functional reserve in 
maintaining the integrity of AP propagation at relatively depolarized potentials. Thus, 
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NaV1.6, and possibly other TTX-S VGSCs, may contribute to the maintenance of 
propagation in the myocardium and to excitation-contraction coupling101.  
 
It has been well established using heterologous systems that TTX-S VGSCs are 
modulated by β subunits3,6,7,11,102. This also occurs in vivo, although the magnitude and 
direction of the changes vary with cell type. Scn1b null ventricular myocytes have 
increased transient and persistent INa and a fraction of this is TTX-S57. Scn1b null 
hippocampal neurons isolated from the CA3 region express decreased levels of NaV1.1 
and increased levels of NaV1.3 without changes in somal INa density compared to WT68. 
Scn1b null cerebellar neurons have altered VGSC localization in the axon initial 
segment and reduced resurgent INa50. In the peripheral nervous system, the voltage 
dependence of TTX-S INa inactivation is shifted in a depolarizing direction in Scn1b null 
small DRG neurons103. In Scn2b null mice, the loss of β2 results in negative shifts in the 
voltage dependence of TTX-S INa inactivation as well as significant decreases in INa 
density in acutely dissociated hippocampal neurons. The integral of the compound AP 
in optic nerve is significantly reduced, and the threshold for AP generation is increased, 
indicating a reduction in the level of functional plasma membrane VGSCs104. In acutely 
isolated small-fast DRG neurons, Scn2b null mice show significant decreases in TTX-S 
INa with no detectable changes in the voltage dependence of activation or inactivation. 
Activation and inactivation kinetics of TTX-S, but not TTX-R, INa are slower due to 
Scn2b deletion. This selective regulation of TTX-S INa is supported by reductions in 
transcript and protein levels of TTX-S Scn1a/NaV1.1 and Scn9a/NaV1.7105. Therefore, β 
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subunits may also contribute to pathogenesis in cardiac disease by disturbing the 
regulation of TTX-S INa in heart as well as in the cardiac innervation.  
 
VGSC β subunits may also contribute to cardiac arrhythmia via neuronal mechanisms 
that include modulation of SCN10A, encoding the TTX-R VGSC NaV1.8, whose 
association with cardiac conduction was identified by GWAS106. This VGSC, originally 
identified in nociceptors and known to associate with β subunits107, is also localized to 
intracardiac neurons, where its blockade markedly reduces AP firing frequency108. 
NaV1.8 current characteristics vary in heterologous systems depending on the type of β 
subunit expressed107,109.  In Scn10a null mice, the cardiac PR interval is shorter than in 
WT littermates, with no differences in other ECG parameters or echocardiographic 
cardiac dimensions and function106.  In addition to NaV1.8, β subunits associate with a 
number of peripheral nerve TTX-S VGSCs, including NaV1.1, NaV1.2, and NaV1.6. Thus, 
through disruptions of some or all of these interactions, β subunit gene mutations may 
generate arrhythmias via neural mechanisms. 
 
VGSC β subunits modulate K+ channels.  
β1 is a multifunctional molecule that is not specific to VGSC complexes. β1 co-
assembles with and modulates the properties of the KV4.x subfamily of channels that 
underlie Ito  in heart and IA in brain37,38,110. Ito is an important contributor to AP 
repolarization in heart111. β1 associates with KV4.3, increases the amplitude of the KV4.3 
current, and modifies KV4.3 gating 37,38. The SCN1B mutation p.R214Q, which 
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selectively affects β1B and not β1, is proposed to contribute to the arrhythmogenesis of 
BrS by concomitantly decreasing INa and increasing Ito36. 
 
Roles of β subunits in cardiovascular pharmacology and treatment.  
β1 expression modulates cardiac VGSC sensitivity to lidocaine block with subtle 
changes in channel kinetics and gating properties112. Flecainide is a class Ic agent that 
is used in provocation tests to unmask the BrS phenotype113 and that reduces 
arrhythmogenesis in patients with LQT3114. Quinidine is a class Ia agent which reduces 
arrhythmogenesis in BrS patients115 and is reasonable for the treatment of electrical 
storm in BrS116. Flecainide and quinidine are pro-arrhythmic and anti-arrhythmic, 
respectively, in the Scn5a+/- BrS mouse model117. In contrast, both flecainide and 
quinidine exert antiarrhythmic effects in Scn3b null hearts through modifying the 
ventricular effective refractory period rather than changes in AP duration118. Although 
both transgenically engineered mouse lines are VGSC loss-of-function BrS models, 
their responses to flecainide appear to be different. This genetically specific response to 
drug was also confirmed in our Scn1b null mice, in which carbamazepine, but not 
lacosamide, failed to block high-frequency firing in nerve119. β subunits not only modify 
the response of NaV1.5 to drug administration, but are also putative drug targets 
themselves. Late INa contributes to heart failure (HF) mechanisms. Suppression of late 
INa but not transient INa in failing cardiomyocytes is beneficial120. Post-transcriptional 
silencing of Scn1b in a HF canine model results in decreased late INa without affecting 
transient INa 121. Based on these results, SCN1B may prove to be a plausible drug target 
in HF. 
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Summary  
Considerable advances have been made in understanding the molecular basis of 
arrhythmia over the past 20 years. From fundamental, single ion channel function under 
physiological conditions to malfunction of defective channels in pathophysiology, from 
simple heterologous expression models to integrative animal models, knowledge in 
pathogenesis of channelopathies is evolving rapidly. Complexities are being added to 
our previous understanding of monogenic diseases whose etiology clearly cannot be 
attributed to the effects of single gene mutations alone. Assignment of causation is not a 
simple task. Common polymorphisms in VGSC α and/or β subunit genes may influence 
the severity of disease-causing mutations. For example, common SCN5A 
polymorphisms differentially modulate the biophysical effects and expression levels of 
disease-causing SCN5A mutations122,123. Expression levels of Scn4b modify conduction 
defect severity caused by a Scn5a mutation in mice92. Deleterious effects of mutations 
can be additive. Longer QTc intervals, a higher incidence of arrhythmia, and more 
severe symptoms are observed in LQTS patients carrying 2 different mutations124. Thus, 
an understanding of a patient’s genetic background is required to correctly interpret a 
disease-causing mutation. Although lacking patient-specific genetic backgrounds, 
transgenic mouse models allow us to investigate cardiac phenotypes at an integrative 
level125 in a relatively “low-noise” genetic background. Thus, in the following chapters, I 
will discuss how I utilized a transgenic mouse model to investigate electrophysiological 
consequence of Scn2b deletion. The observed cardiac phenotypes, including ventricular 
and atrial arrhythmia, and insights into their underlying mechanisms will be discussed. 
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In the future, combining findings from GWAS126 and patient-specific induced pluripotent 
stem cell (iPSC) models127 will allow us to have better insights into genotype-to-
phenotype correlations, and provide a basis for more precise risk stratification and 
prognosis estimation. In addition, patient-specific iPSC models will be invaluable tools 
for drug screening128 and  the development of individualized therapies. 
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CHAPTER II 
Scn2b deletion in mice leads to ventricular arrhythmia 
 
Work presented here includes collaborative efforts contributed by Dr. B. Cicero Willis 
and Dr. Xianming Lin from the laboratories of Dr. Jose Jalife at the University of 
Michigan and Dr. Mario Delmar at New York University, respectively. Dr. B. Cicero Willis 
and I performed the optical mapping studies together. Dr. Xianming Lin performed 
super-resolution patch clamp recording. I performed the remainder of the work. 
 
Introduction  
As discussed in chapter I, β subunits regulate sodium current (INa) density, kinetics, 
voltage dependence of gating, and channel cell surface expression. In addition,  
subunits function as cell adhesion molecules (CAMs)8,9. Considering their 
multifunctional roles in channel modulation and cell-cell communication, it is not 
surprising that mutations in the genes encoding the VGSC β subunits have been 
implicated in cardiac arrhythmia129. Mutations in SCN2B, encoding VGSC β2, are 
associated with atrial fibrillation (AF) and Brugada syndrome (BrS) in human 
patients48,130, suggesting that β2 may play important roles in establishing or maintaining 
normal cardiac electrical activity. β2 is covalently linked to VGSC α subunits via 
disulfide bonds12, including the major cardiac VGSC, Nav1.57, and is known to enhance 
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the trafficking of neuronal α subunits (including NaV1.1, NaV1.2, NaV1.3, NaV1.6, and 
NaV1.7) to the plasma membrane as well as modulate the voltage dependence of 
channel gating104,105. Central neurons isolated from Scn2b null mice have reduced cell 
surface VGSCs and comparably reduced INa density, altered voltage dependence of 
inactivation, and increased susceptibility to seizures104. Similar changes in INa have 
been shown in Scn2b null nociceptive neurons105. In contrast to neurons, the role of 
Scn2b in heart is not well understood. Co-expression of a SCN2B mutant protein linked 
to AF and BrS with NaV1.5 in a heterologous system revealed a reduction in INa density 
compared to expression of NaV1.5 alone, suggesting cardiac VGSC loss-of-
function48,130. However, the role of 2 in heart has not been explored in vivo. Here, I test 
the hypothesis that β2 plays critical roles in cardiac excitability.  
 
Scn2b deletion results in decreased INa density in ventricular myocytes. 
I compared whole-cell INa in acutely isolated Scn2b null and WT ventricular myocytes. 
Scn2b null myocytes showed a significant reduction in total INa density (Fig. 2A), a 6.5 
mV hyperpolarizing shift in the voltage-dependence of activation, and decreased slope 
factor (κ) of the activation curve compared to WT (Fig. 2B). There were no observable 
differences in the voltage-dependence of inactivation (Fig. 2C), or the kinetics of 
recovery from inactivation between genotypes (Fig. 2D). There were also no observable 
changes in the level of persistent INa (Fig. 2E) or the kinetics of inactivation measured at 
-45 mV (Fig. 2F-G) (Table 2). Taken together, these data indicate that the principal role 
of VGSC β2 subunits in ventricular myocytes is to regulate INa density, similar to what 
we have observed previously in central and peripheral neurons104,105. 
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Figure 2 INa recordings from ventricular cardiomyocytes 
A. Scn2b null ventricular myocytes have significantly decreased INa over a voltage range 
from -50mV to -10mV (p<0.05, Scn2b null: n=12, N=6; WT: n=9, N=6). B, Scn2b 
deletion shifts the voltage-dependence of activation in the hyperpolarizing direction by 
6.5 mV (p=0.019, Scn2b null: n=12 N=6; WT: n=9 N=6) and decreases the slope factor 
κ (p=0.002, Scn2b null: n=12 N=6; WT: n=9 N=6). C. There were no differences in 
steady-state inactivation between wildtype and null cells. D – G. Scn2b deletion has no 
effect on the time dependence of recovery from inactivation, persistent INa, or the 
kinetics of inactivation. Significance determined using Student’s T test or Mann-Whitney 
Rank Sum test. N is the number of animal and n is the number of the cell.  
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Table 2 INa Biophysical Properties 
 
WT Scn2b null p-value 
 N=6 N=6  
Voltage dependence of activation 
  
V1/2(mV)  -55.542±1.435 -62.065±1.918 p=0.019 
κ 6.201±0.257 4.057±0.361 p=0.002 
n 9 12 
 
Voltage dependence of inactivation 
  
V1/2(mV)  -91.237± 1.611 -92.368± 2.270 p=0.708 
κ -6.004±0.183 -6.129±0.17 p=0.627 
C 0.0337± 0.00747 0.0207± 0.0112 p=0.383 
n 9 12 
 
Kinetics of inactivation 
  
τslow (ms) 5.650± 0.726 4.184± 0.715 p=0.169 
n 9 9  
τfast (ms)  2.003± 0.24 1.65± 0.204 p=0.276 
n 9 12  
Steady-state persistent current  
  
% of peak current  3.87±0.492 2.7±0.428 p=0.087 
n 9 11 
 
Kinetics of recovery 
  
τ (ms) 10.359±1.425 8.551±1.166 p=0.336 
n 8 10 
 
Data are mean ± SEM. Kinetics of inactivation were recorded at a test potential of  
-45 mV. Persistent INa was recorded at a test potential -45 mV, 50-52 ms after the 
voltage step. *Significance was determined using Student t-test with p<0.05.  
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No changes in the distribution of sodium channels recorded from T-tubules or 
crest regions. 
VGSCs are differentially localized in the heart. The tetrodotoxin-resistant (TTX-R) 
channel, NaV1.5, is preferentially localized at the intercalated discs and lateral 
membrane, while multiple tetrodotoxin-sensitive (TTX-S) VGSCs, including NaV1.1, 
NaV1.3, and NaV1.6, are localized in the t-tubules22,131. β2 subunits have been shown to 
associate biochemically with NaV1.522 and to localize preferentially at intercalated 
discs131. To investigate the whether there is a change of sodium channel redistribution 
at the subcellular level that may contribute to the current change, we performed super-
resolution scanning patch clamp recordings of INa at the t-tubules and at the cell crests 
as in132. Fig. 3 presents frequency histograms for the number of channels detected 
within a patch, estimated from the average peak current amplitude (voltage step to −30 
mV from a holding potential of −120 mV), and a unitary conductance of 10 pS133.  The 
histogram obtained from recordings at the t-tubules showed a Gaussian distribution 
(Fig.3A), while the data obtained at the cell crest was more bimodal (3B), consistent 
with previous observations133. No difference was apparent between genotypes. 
Combined with previous finding that subcellular localization of β2 is at the intercalated 
disc131, we speculated that sodium current are more affected at the intercalated discs.   
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Figure 3 No changes in the distribution of sodium channels recorded from the T-
tubules or from the crest regions 
Ordinates show percent of recordings (relative to total number of attempts). Abscissae 
show number of open channels detected. Number of open channels in each recorded 
patch was estimated from the average peak current amplitude during a voltage step to 
−30 mV from a holding potential of −120 mV, and an estimated unitary conductance of 
10 pS. The number of separate recordings reported in each histogram is indicated in the 
top left of each panel (WT, N=4; Scn2b null, N=3). The pipette was placed on the 
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opening of the T-tubules (top) or on the crest (bottom). Significance determined using 
Fisher's exact test. N is the number of mice and n is the number of patch. 
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Scn2b null hearts have impaired impulse propagation in the right ventricular 
outflow tract region (RVOT) 
To test the hypothesis that cardiac conduction may be compromised due to the loss of 
INa in Scn2b null ventricle, we performed optical mapping of ex vivo Langendorff 
perfused heart preparations (Fig. 4). Slowed conduction was observed in the Scn2b null 
RVOT, but not the RV, region compared to WT (Fig. 4 A-C). To examine excitability 
changes in the RVOT region more closely, I performed current clamp recordings of APs 
in Scn2b null myocytes and WT myocytes isolated from the RVOT. While I observed 
trends toward decreased maximum upstroke velocity at different pacing cycle lengths 
and depolarized resting membrane potential in Scn2b null cells compared to WT cells 
(Fig. 5B and C), these changes did not reach significance. APDs at early phases 
(APD30-APD50) were unchanged between genotypes (Fig. 5D). In contrast, late phase 
APDs (APD70-APD90) were significantly prolonged in Scn2b null myocytes compared to 
WT (Fig. 5E, G). Consistent with this prolonged, late phase APD, we observed a 
significantly higher incidence of early afterdepolarization (EADs)134 in Scn2b null 
myocytes (9 out of 21 cells) compared to WT (1 out of 15 cells) (Fig. 5F, P = 0.024).  
 
  
 39 
 
 40 
Figure 4 Conduction velocity is decreased in the Scn2b null right ventricular 
outflow tract (RVOT) region 
A. Conduction velocity is significantly decreased in the RVOT region but not right 
ventricular (RV) free wall (Scn2b null: N=9; WT: N=11) paced at various cycle lengths 
(CL=100ms p=0.011; CL=125ms, p=0.032; CL=150ms *p=0.015; CL=175ms p=0.012; 
Student’s T test, *Mann-Whitney Rank Sum Test where applicable). B. Langendorff 
heart preparation during optical mapping. Box shows corresponding region for 
measurement. C. Two representative activation maps from Scn2b null and WT 
preparations at 150 ms pacing cycle length. White lines indicate isochrone lines. 
Numbers on each line indicate time in msec. Note that isochrone lines are more 
crowded in Scn2b null hearts, indicating conduction slowing in the RVOT. 
 
  
 41 
 
Figure 5 AP recordings from single RVOT myocytes. 
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A. No differences between genotypes in AP amplitude when paced at 1-5 Hz (WT: N=8, 
n=10-14; Scn2b null: N=5, n=12-16). B. Scn2b null hearts exhibited a trend toward 
decreased AP maximum upstroke velocity (p=0.098-0.418 from 1-5Hz; WT: N=8, n=10-
14; Scn2b null: N=5, n=11-16). C. Scn2b null myocytes showed a slight depolarization 
in resting membrane potential (p=0.223; WT: N=8, n=14; Scn2b null: N=5, n=18). D. 
Similar time courses of early phase repolarization (APD25-50) between WT and Scn2b 
null myocytes. E. In contrast, the late phase APD values (APD70-90) were significantly 
prolonged in Scn2b nulls (p=0.005-0.021). F. Scn2b null myocytes exhibited a higher 
incidence of early afterdepolarizations (EADs) than WT (p=0.024). A representative 
Scn2b null EAD trace is shown in the lower panel. G. Representative AP traces from 
each genotype. The final phase of the Scn2b null AP is prolonged compared to WT. The 
trace was paced at 4Hz. Significance was determined using Student’s T test, Mann-
Whitney Rank Sum Test, or Fisher’s exact test where applicable. 
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Scn2b null ventricles are more arrhythmogenic than WT  
To assess the susceptibility of Scn2b null ventricles to arrhythmia, we performed optical 
mapping experiments with simultaneous, volume-conducted ECGs in isolated hearts 
(Fig. 6). Episodes of spontaneous, non-sustained ventricular tachycardia (NSVT) and 
premature ventricular complexes (PVCs) were observed in 3 and 4 out of 10 Scn2b null 
hearts, respectively, but not in the 11 WT hearts tested (Fig. 6A). Fig. 6B and C show 
an anatomical view of the heart under the camera during the optical mapping and 
epicardial activation during a sinus beat, respectively. As expected from previous 
studies135, during the sinus beat, two breakthroughs appeared on the LV and RV free 
wall close to the apex and then the excitation wavefront propagated towards the base of 
the heart. All spontaneous aberrant rhythm events appeared with a premature 
ventricular complex (PVC) within a mean time window of 25-26 min following 
cannulation and before any pacing or pharmacological maneuvers were performed (Fig. 
6D). Episodes of spontaneous NSVT were recorded and phase maps were generated 
to analyze activation patterns during tachycardia (Fig. 6D-F). Rotors were observed (for 
example, see Supplemental movie 1), implicating functional re-entry as the underlying 
mechanism of arrhythmia in Scn2b null hearts. Singularity points, the organizing centers 
of each rotor, were concentrated in the Scn2b null RVOT region (Fig. 6E), suggesting 
that wavebreaks were more likely to occur in this area. Interestingly, rotors were not 
confined to the RVOT, but were observed to meander to the left and right anterior 
ventricular free walls over time (Fig. 6F), giving rise to the polymorphic appearance of 
the ECG (Fig. 6D). Closely coupled PVCs served as triggers for NSVT initiation in 
Scn2b null hearts. Chronological snapshots taken from a phase movie of a Scn2b null 
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heart capturing initiation of an episode of spontaneous polymorphic VT illustrate that the 
interplay between a PVC and the arrhythmogenic substrate that led to arrhythmia (Fig. 
7).  During the sinus beat preceding VT, the epicardium was homogeneously activated 
from apex to base (Fig. 7A). A PVC then emerged (Fig. 7 B-C) as an epicardial 
breakthrough on the anterior RV free wall near the apex. This premature impulse 
traveled to the RVOT region and was blocked, likely due to prolonged APD and 
maintenance of refractoriness (Fig. 7 C-D). The impulse then detoured to the LV, 
circumventing the RVOT. When the RVOT was finally activated, due to slowed impulse 
conduction within this region, the rest of the heart had finished repolarizing and was 
ready for re-excitation. As a result, the excitation wave front turned at the RVOT and 
initiated a rotor (Fig. 7 E-F). 
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Figure 6 Arrhythmic events captured in Scn2b null hearts by optical mapping. 
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A. Incidence of PVC and VT in WT (0 out of 11 hearts) vs Scn2b null (4 out of 10 and 3 
out of 10 hearts, respectively) (p=0.02 and p=0.09, respectively, Fisher’s Exact Test). . 
Anatomical view of the heart under the camera during the optical mapping. LV: left 
ventricle, RV: right ventricle, RVOT: right ventricular outflow tract, RCA: right coronary 
artery. C. Activation map of a sinus beat. Normal epicardial activation during the sinus 
beat had two breakthroughs on the LV and RV free wall close to the apex and then the 
excitation wavefront propagated towards the base of the heart. White lines are 
isochrones lines (in msec).  D. Volume conductive pseudo ECG (bipolar mode, frontal 
plane) showed 3 episodes of polymorphic NSVT and PVC. Each episode of VT was 
triggered by a PVC, sharing the same morphology as a single independent PVC, 
indicating a focal source of this triggering ectopic beat. The polymorphic VT had a 
frequency transition from 24.7 Hz to 20.8 Hz.  E. Singularity point map. Each singularity 
point is the organization center where the potential phases merge. Singularity map 
shows that the location of the rotors (white dots) remained in the RVOT region during 
most of the recording period. F. Two phase map snapshots of two rotors during VT. 
Rotors are dynamic, spin in multiple directions, and can meander to other regions, 
giving rise to the polymorphic appearance of ECG. 
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Figure 7 Proposed mechanism of VT initiation and rotor formation. 
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Chronological snapshots of a phase movie that captured initiation of an episode of 
spontaneous polymorphic VT illustrate that the interplay between a PVC and the 
arrhythmogenic substrate of Scn2b null hearts leads to arrhythmia.  A. During the sinus 
beat preceding VT, the epicardium was homogeneously activated from apex to base. B 
and C. A PVC then emerged and resulted in breakthrough to the epicardium in the 
anterior RV free wall close to apex. C and D. The early impulse traveled to the RVOT 
region where it was blocked due to prolonged APD and increased refractoriness.  E. 
Thus the impulse detoured to the LV and circumvented the RVOT. When the RVOT was 
finally activated, due to slowed conduction within this region, the rest of the heart had 
finished repolarization and was ready for re-excitation. E and F. As a result, the 
excitation wave front turned around at the RVOT and initiated a rotor. Inset: 
Corresponding ECG.  
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Discussion 
 
Scn2b null mice mimic human Brugada syndrome. 
BrS is a rare, inherited cardiac disease in structurally normal hearts that results in 
increased risk of ventricular fibrillation leading to sudden cardiac death136. The 
phenotypic characterization of BrS in human patients is J-point and ST segment 
elevation in right precordial leads (V1 to V3) with pseudo-right bundle branch block137. 
While only 30–35% of diagnosed BrS cases are attributable to pathogenic variants in 
known genes, 25–30% of these result from reduction of INa 138, similar to what we have 
observed in Scn2b null ventricular myocytes. Two hypotheses, focusing on 
repolarization and depolarization, respectively, have been proposed to explain BrS70. 
Both hypotheses predict that, similar to our mouse model, the RVOT is the most 
affected region in human heart. Both slowed conduction and prolonged activation-
recovery time (ARI) are observed in BrS patients using ECG imaging techniques139, 
suggesting that depolarization and repolarization abnormalities may exist in BrS 
concomitantly.  
 
Mutations in SCN5A have been implicated as causal in BrS140. Compelling evidence 
from clinical studies of endocardial141,142 or epicardial mapping143,144, shows conduction 
delay in the RVOT, suggesting that aberrant depolarization underlies BrS70. Our data in 
Scn2b null mice demonstrate a reduction in INa with a corresponding decrease in 
impulse propagation. Similar to human BrS, the RVOT region is preferentially affected in 
our model.  
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Prolongation of repolarization has also been observed in the RVOT region of BrS 
patients145 146 139. This is thought to contribute to QT prolongation in right precordial 
leads under pharmacological challenge147.  In addition, an augmented AP notch may 
reduce the availability of calcium current in human heart, resulting in delay in the 
second upstroke and the onset of phase 3, resulting in longer AP duration148,149. In 
contrast to humans, the mouse cardiac AP lacks a clear plateau phase, and 
consequently shows no spike and dome upon INa reduction150. APD shortening, rather 
than lengthening, was observed in the right epicardium in the murine Scn5a+/− model of 
BrS compared to WT, and was shorter than the corresponding endocardial APD, 
creating increased right ventricular repolarization gradients151. In contrast, a significant 
prolongation of APD90 was observed in the Scn2b null model, mimicking clinical findings. 
Recently, model-independent interactions between IK1 and INa were revealed, 
implicating reciprocal modulation of expression of Kir2.1 and NaV1.5 within a 
macromolecular channel complex152. Because Nav1.5 and 2 are covalently linked in 
heart22, it is likely that 2 subunits also associate with the Kir2.1/Nav1.5 complex at the 
intercalated disc and that both are down-regulated in Scn2b null hearts. Thus, we 
propose that reduced IK1 may contribute to the final AP phase prolongation in Scn2b null 
myocytes.  
 
PVC and arrhythmogenesis in BrS and Scn2b null hearts 
Trigger elimination, focal ablation of PVCs originating from the RVOT153, and substrate 
modification by epicardial ablation of arrhythmogenic sites in the RVOT anterior free 
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wall143 have been demonstrated to be effective in preventing arrhythmic events in 
human BrS patients. Thus, PVCs are proposed to serve as triggers in arrhythmogenesis. 
The timing of emergence and spatial orientation of the excitation wavefront of the 
ectopic beat are key factors in arrhythmia initiation. In animal BrS models, phase 2 re-
entry has been proposed as the mechanism of extrasystole, which may further 
degenerate into ventricular fibrilllation154. Accordingly, phase 2 re-enty based PVCs are 
proposed to originate from the RVOT and be short coupled. Consistent with this, pace 
mapping shows that PVCs in patients with BrS frequently originate from the free-wall 
region of the RVOT155. However, PVCs that initiate VT are not observed exclusively 
from the RVOT156 or with short coupling interval156,157, indicating high variability in the 
onset mode of arrhythmia in BrS. More interestingly, when patients carry SCN5A 
mutations, they are less likely to have PVCs from the RVOT158. In previous BrS murine 
model studies, PVCs were demonstrated to play important roles in initiating re-entrant, 
spontaneous polymorphic ventricular tachycardia159. Sites of origin coincided with 
localized areas of high repolarization heterogeneity. In our Scn2b null model, we found 
that every recorded VT episode occurred following a PVC, suggesting a requirement for 
PVCs to serve as triggers. In addition, epicardial breakthrough of the initiating PVC was 
observed to be located at the RV free wall near the apex rather than in the RVOT. We 
found no differences in the coupling interval between VT-initiating PVCs and PVCs that 
did not trigger VT (Figure 8). Because the morphologies of these PVC types were 
similar, we propose that the origins of the PVCs were focal. Thus, the subsequent 
occurrence of VT was dependent on the repolarizing state of the preceding sinus beat, 
in which case the repolarization or refractoriness was dynamic. Unlike early 
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repolarization syndrome, a variant in the J-wave syndrome spectrum often has VF 
episodes initiated by PVCs with a short-long-short sequence157, BrS has a more 
complex and dynamic mode of onset of VT/VF. 
  
 53 
 
Figure 8 No differences in PVC coupling interval. 
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A. An independent PVC and a PVC that triggered VT. B. No differences were found in 
the coupling interval between these two categories in Scn2b null heart (p=0.459, Mann-
Whitney Rank Sum Test). Numbers below the box plot are the total number of PVCs 
that were included for analysis in each group.  
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CHAPTER III 
Conduction system is intact in Scn2b null mice 
 
Work presented here includes collaborative efforts contributed by Dr. Roberto Ramos 
Mondragon from the laboratory of Dr. Hector Valdivia at the University of Michigan. Dr. 
Roberto Ramos and I performed the intracardiac recordings together. I performed the 
remainder of the work. 
 
Introduction  
The cardiac conduction system is specialized myocardium composed of the sino-atrial 
node, the atrio-ventricular node and the His-Purkinje system, coordinating electrical 
propagation to allow both sequential and synchronous contraction between and within 
chambers160. Mutations in sodium channel genes including SCN5A, SCN1B and 
SCN10A have been associated with progressive cardiac conduction disorders 
(PCCD)161 and sick sinus syndrome162,  which are characterized by progressive 
impairment of the conduction system and bradycardia. NaV1.5 are expressed in 
conduction system and in the regions surrounding the SA and AV node163. Since a 
majority of mutations that associated with PCCD are characterized as sodium channel 
loss-of-function164, I proposed that loss of β2 may also affect cardiac conduction system. 
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To test this hypothesis, I performed body surface ECG and intracardiac recordings from 
in vivo hearts and pseudo-ECG on surgically denervated hearts.     
  
ECGs from Scn2b null mice suggest bradycardia 
Two sets of animals at different ages, 3 months and 7-9 months, were used for in vivo 
ECG recordings. Reduced heart rate (HR) was observed in Scn2b null mice compared 
to WT in the 3 month-old group (Fig. 9A) with a trend to slowed heart rate in the 7-9 
month-old group (Fig. 9B) (P = 0.025 and P = 0.092, respectively for the groups). In 
contrast, HRs in denervated ex vivo Sc2b null hearts (isolated from 3-6 month old mice) 
were indistinguishable from that in WT hearts, suggesting altered autonomic control, 
rather than intrinsic cardiac rhythm alterations in Scn2b null mice (Fig. 9C). There were 
no observable changes in other ECG parameters, including PR interval, P wave 
duration, QRS duration and QT interval (Table 3). To circumvent known issues in 
correcting QT intervals for heart rate in mice, we placed an octapolar 
stimulating/recording catheter into the right heart chamber to directly pace the atrium 
and entrain the whole heart at a fixed pacing cycle length of 100ms. QT intervals were 
then measured during pacing and compared between genotypes without correction (Fig. 
10). No differences between the two genotypes were found using this method, 
suggesting that the regional slowed conduction and slight increase in APD observed at 
the single cell level in Scn2b null myocytes were not of sufficient magnitude to be 
reflected on the ECG (Table 3).  
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Figure 9 Heart rate was slightly decreased in Scn2b null mice. 
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A. Decreased HR was observed in Avertin anesthetized 3 month-old Scn2b null mice 
during ECG recordings  (p=0.025) . B. A similar trend of HR reduction was observed in 
7 – 9 month-old mice anesthetized with Isoflurane (p=0.092). C. There were no 
differences in HR observed in ex vivo hearts (Scn2b null: 315±17 bpm; WT: 319±20 
bpm) (p=0.863). All panels:  Numbers on the bars indicate the number of animals tested.  
Significance determined with Student’s T test. 
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Figure 10 Surface ECG during atrial pacing. 
The QT interval was measured when the atrium was paced at a constant cycle length 
(100ms) to avoid inappropriate correction.  
  
 60 
Table 3 ECG Parameters 
Age Anesthetics Parameter WT Scn2b null P-value 
2-3 month Avertin Heart Rate (HR) bpm 413±12 368±14 p=0.025 
 N=10 N=9  
P-wave duration (ms) 10.24±0.71 9.18±0.9 p=0.37 
PR interval (ms) 44.2±1 44.02±1.97 p=0.93 
QRS duration (ms) 11.62±0.47 12.39±0.56 p=0.32 
QT interval (ms) 43.4±0.3 42.5±0.38 p=0.093 
 N=7 N=6  
7-9 month Isoflurane  Heart Rate (HR) bpm 509±19  464±15 p=0.092 
P-wave duration (ms) 12.2±0.49 12.82±1.31 p=0.73 
PR interval (ms) 42.89±2.08 39.86±0.93 p=0.157 
QRS duration (ms) 10.25±0.62 9.5±0.29 p=0.239 
QT interval (ms) 42.68±2.46 41.1±1.26 p=0.537 
 N=5 N=8  
Paced QT interval (ms) 
At 100ms pacing cycle 
length  
44.11±1.7 45.31±1.06 p=0.54 
 N=5 N=7  
Data are mean ± SEM. N = number of animals. 1.2% Avertin, 0.23 ml per 10 g of body weight, 
was administered IP. 1.5% isoflurane was used for acquisition of surface ECGs. Paced QT 
interval was measured during intracardiac recording with animals maintained under 2% 
isoflurane. *Significance was determined with Student t-test with P < 0.05. 
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Scn2b null mice exhibit a normal cardiac conduction system  
Loss-of-function mutations in SCN5A have been associated with progressive cardiac 
conduction defects (PCCD)165. To assess whether the cardiac conduction system was 
also affected in Scn2b null, we performed intracardiac recordings to measure the 
conduction time for each segment along the conduction pathway, as well as to assess 
the electrophysiological properties of the sinoatrial node (SAN) and atrio-ventricular 
node (AVN). Neither the atrial-His conduction time, His-ventricular conduction time, 
SAN recovery time, AVN refractoriness, nor Wenckebach periodicity were different from 
WT mice (Table 4). These data suggest that the cardiac conduction system is intact in 
the Scn2b null heart. 
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Table 4 Intracardiac electrophysiological values 
 WT Scn2b null P value 
AH Interval (ms) 27.2±2 27.8±2.5 p=0.87* 
HV Interval (ms) 9.5±0.5 10.4±0.6 p=0.31 
 N=5 N=7  
SNRT100 (ms) 74.9±11.9 62.4±11 p=0.23* 
SNRT90 (ms) 106±9.9 83.1±14.3 p=0.22 
AVERP100 (ms) 47.6±2.6 48.5±2.3 p=0.79 
 N=7 N=8  
AVERP80 (ms) 58.1±2.2 58.6±2 p=0.89 
AERP100 (ms) 26.3±2.4 22.3±1.8 p=0.2 
AERP80 (ms) 19.8±1.1 19.4±1 p=0.78 
 N=7 N=7  
WP (ms) 72.6±2.1 73.3±1.1 p=0.77 
WP2:1 (ms) 53.7±2.1 52.2±1.6 p=0.59 
 N=7 N=8  
VERP100 (ms) 45.2±2.5 38.7±3 p=0.13 
 N=6 N=6  
VERP80 (ms) 42.5±3 39.2±3.2 p=0.48 
 N=4 N=5  
Values are means ± SE; N, number of mice. AH, interval from atrial to His-
signal; HV, interval from His to first QRS- movement in surface-ECG; SNRT, 
sinus-node recovery-time; AVERP, atrial-ventricular effective refractory 
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period; AERP, right atrial effective refractory period; WP Wenckebach-
periodicity, WP2:1, Wenckebach-periodicity at 2:1 conduction; VERP, right 
ventricular effective refractory period. Subscripts indicate S1S1 drive cycle 
lengths. Student t-test and *Mann-Whitney rank sum test. 
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Discussion 
 
Conduction system and autonomic control in Scn2b null mice 
Among murine models that carry sodium channel mutations, Scn5a 
haploinsufficiency166 and Scn3b null mice63 are most phenotypically similar to our Scn2b 
null mice. Both of the two model human BrS and concomitantly have atrial phenotype 
including sinus node exit block17 and AF susceptibility64. Since the connection between 
SCN5A and Progressive Cardiac Conduction Defects (PCCD) is well established165, it is 
reasonable to expect impairment of conduction system in both Scn5a+/- 167,168 and 
Scn3b-/- mice64. However, Scn2b null mice did not exhibit abnormal conduction, which 
may attribute to two reasons. Firstly, both Scn5a heterozygotes (Hz) and Scn3b KO are 
on the inbred strain of 129SvEv, ours is on C57BL6. Previous study has demonstrated 
that the severity of conduction defects is strain dependent due to genetic background. 
Scn4b was identified as the responsible gene, which had lower expression in 129P2 
than FVB/NJ strain, giving rise to a more severe phenotype92. Secondly, the tissue 
distribution of  subunits may also play a role in contributing to conduction system 
phenotype. SCN3B is highly expressed in the ventricles and Purkinje fibers but not in 
atrium in sheep heart20, suggesting its importance in the conduction system. Further 
investigations are needed to profile tissue distribution of 2 in the heart. 
 
Heart rate was slower in Scn2b deficient mice regardless of age and types of 
anesthetics used, whereas no difference in heart rate were found in pharmacologically 
denervated heart. Thus altered autonomic control may account for these findings. 
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Unlike NaV1.5, 2 is also extensively expressed in central and peripheral nervous 
system, modulating other neuronal sodium channels104,105,169, potentially contributing to 
autonomic control of the heart.   
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CHAPTER IV 
Higher Susceptibility to Atrial Arrhythmia in Scn2b Null Mice 
Work presented here includes collaborative efforts contributed by Dr. B. Cicero Willis 
and Dr. Roberto Romas Mondragon from the laboratories of Dr. Jose Jalife Lab and Dr. 
Hector Valdivia, respectively. Dr. B. Cicero Willis and I performed the optical mapping 
together. Dr. Mondragon and I performed intracardiac recordings together. Masson’s 
trichrome staining was performed by Dr. Erby Wilkenson in the ULAM In-Vivo Animal 
Core as fee-for-service. I performed the remainder of the work. 
 
Introduction  
Atrial fibrillation (AF) is the most common sustained arrhythmia disease with a 
prevalence of 1% to 2% in the US170. Mutations that affecting both sodium channel α 
and β subunits have been linked to AF171. Two missense mutations in SCN2B have 
been revealed in human AF patients48, suggesting an important role of β2 in the heart. 
To study the role of Scn2b in atria, I investigated the atrial phenotype of Scn2b null mice 
using optical mapping and intracardiac recording. 
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Scn2b null mice have increased susceptibility to atrial fibrillation in vivo 
Both gain- and loss-of-function mutations in SCN5A have been linked to atrial 
fibrillation172. For SCN5A loss-of-function mutations, lower conduction velocity and 
shortened APD give rise to shortened wavelength, facilitating stable re-entry and thus 
providing a substrate for atrial fibrillation173. To test whether Scn2b null hearts are also 
prone to atrial fibrillation, I applied burst pacing to induce atrial tachyarrhythmia before 
and after carbachol administration. I defined atrial fibrillation/ tachyarrhythmia (AF/AT) 
as episodes of 1 sec or greater in duration, before or after carbachol administration, 
during burst pacing or the S1-S2 protocol. Using these criteria, I found that AF/AT 
susceptibility was significantly higher in Scn2b null mice (7 out of 9) compared to WT 
mice (1 out of 7) (P = 0.02, Fig. 11A). The durations of induced AF/AT were variable in 
Scn2b null mice, ranging from just over 1 sec to as long as 11 min (Fig. 11B). In 
contrast, the majority of AF/AT episodes in WT mice had durations of less than 1 sec. 
Fig. 11C (center and right panels) shows a representative surface ECG lead-II trace and 
atrial electrogram acquired during atrial fibrillation and flutter in a Scn2b null mouse.  
This is compared to traces from a WT mouse (left panels) that was resistant to induction 
of tachyarrhythmia. In the Scn2b null example, the atrial electrogram is more complex 
and fractionated during atrial fibrillation than during atrial flutter, as indicated.  
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Figure 11 Scn2b null atria are more susceptible to AF. 
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AF/AT was defined as episodes lasting longer than 1 sec either before or after 
carbachol administration. Animals that had at least one AF/AT episode that lasted 
longer than 1 sec were considered to be inducible. A. Scn2b null mice (7 out of 9 
animals) were more susceptible to atrial arrhythmia than WT mice (1 out of 7 animals) 
(p=0.02, Fisher’s exact test, one tailed). B. Distribution of the durations of all AF/AT 
episodes recorded in Scn2b nulls. Most durations ranged from 1.1 sec to 60 sec, with 
the longest episode lasting 11 min. The majority of episodes recorded in WT were 
shorter than 1 sec. C. Representative surface ECG and atrial electrogram from each 
group. Under 5-sec 50 Hz burst pacing with carbachol administration, AF and atrial 
flutter could be induced in Scn2b nulls but not in WT. During AF, the atrial electrogram 
was more disorganized. Numbers on the bars indicate the number of animals tested. 
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Re-entry underlies the mechanism of atrial fibrillation in Scn2b null atria 
To determine the mechanism of atrial arrhythmia in Scn2b null hearts, I performed 
optical mapping in isolated ex vivo atrial preparations (Fig. 12A). Consistent with our in 
vivo observations, I was able to induce AF/AT in these preparations by burst pacing in 5 
of 11 Scn2b null atria compared to 1 of 10 WT atria prior to the application of carbachol 
(300 nM, P = 0.0725). As expected, carbachol administration increased the level of 
AF/AT induction in both genotypes (6 of 11 Scn2b null vs. 3 of 10 WT, P = 0.39). Phase 
movies recorded during AF/AT in Scn2b null atria showed variable forms of rotors, 
which served as drivers to maintain the atrial arrhythmia. For example, Fig. 12B and 
Supplemental movie 2 demonstrate AF/AT driven by a single rotor in the right atrium. 
Fig. 12C and Supplemental movies 3 and 4 show AF/AT driven by two rotors in the 
figure-of-eight conformation (2 count-rotating rotors share common pathway) in the right 
atrium prior to carbachol administration and then driven by single rotor in the pulmonary 
vein (PV) region of the left atrium after carbachol. Fig. 12D and Supplemental movie 5 
show AF/AT driven by three independent rotors at different dominant frequencies (17.7 
Hz and 26.5 Hz respectively).  One rotor was located in the right atrium, while the other 
two, with figure-of-eight configuration at the higher common frequency, were located in 
the PV region. In this case, the AF/AT terminated and then was spontaneously re-
initiated by a sinus beat due to wavebreak in the right atrium. This re-initiated AF/AT 
was sustained by a single rotor in the right atrium (Fig. 12D). Spontaneous AF/AT was 
also observed in one Scn2b null atrium but not in any of the WT atrial preparations, 
suggesting higher atrial arrhythmogenecity in the mutant animals (Fig. 13). Taken 
together, the dynamic, complex, and non-hierarchical organization of rotors in Scn2b 
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null atria suggest that the substrates for AF/AT may be functionally and anatomically 
heterogeneous. 
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Figure 12 Complex and dynamic rotors underlie the mechanism of AF in Scn2b 
null atria. 
A. Anatomical view from posterior of the atrial preparation under microscope (left) and 
camera (right). (SVC: superior vena cava, SAN: sino-atrial node, IVC: inferior vena cava, 
PV: pulmonary veins) Pacing was at the edge of the right atrium appendage. B. Pacing-
induced AF was driven by a single rotor in the right atrium. C. Induced AF was driven by 
two counter-rotating rotors (figure-of-eight re-enty) with 1:1 conduction to the left side. 
After carbachol perfusion, AF was driven by a single rotor located in the left atrium PV 
region with 2:1 conduction to the right side, resulting in twice the dominant frequency in 
left compared to the right. D. AF was driven by three different rotors spinning at 17.7 Hz 
and 26.5 Hz in right and left atrium, respectively (upper left and lower left rotors, 
respectively). After its termination, the AF was spontaneously re-initiated by the 
wavebreak occurring in the right atrium (upper right and lower right). The resultant 
single rotor then drove the entire episode at 27.7 Hz in the right atrium with 1:1 
conduction to the left. A volume conductive bipolar atrium electrogram showed two 
corresponding episodes of AF (bottom atrial ECG trace). 
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Figure 13 Spontaneous atrial tachyarrhythmia in an ex vivo atrial preparation. 
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Sudden acceleration of the atrial bipolar electrogram was observed in one of the Scn2b 
null atria but not in WT. No electrical pacing or drug was applied when the atrium 
developed tachyarrhythmia. Multiple episodes of atrial arrhythmia were observed, the 
longest episode lasted for 24.5 sec at a frequency of ~20 Hz. The morphology of 
tachyarrhythmic beats is different from sinus beats, suggesting that this was not simply 
an acceleration of sinus automaticity.   
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APD is heterogeneously prolonged in Scn2b null atrium 
In contrast to the results in the RVOT region, I observed no changes in atrial conduction 
velocity between genotypes (Fig. 14). AP recordings from single right atrial myocytes 
showed no differences in amplitude, maximum upstroke velocity, or resting membrane 
potential between groups (Fig. 15A). While there was a trend toward increased APD25-30, 
I observed a significant increase in the later phases of the APD (APD50-90) in Scn2b null 
myocytes compared to WT myocytes (Fig. 15B). Fig. 15C presents representative, 
superimposed AP wave forms from each genotype to illustrate the AP prolongation in 
Scn2b null atrial myocytes compared to WT. In Fig. 15D I plot the range of APD values 
for ventricular (upper panel) and atrial (lower panel) myocytes of each genotype to 
illustrate the degree of heterogeneity in the Scn2b null atrial data set. I propose that this 
dispersion of repolarization in individual cells generates functionally heterogeneous 
substrates in the Scn2b null atrium that predispose the tissue to wavebreak during fast 
pacing.   
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Figure 14 Conduction velocity is not altered in Scn2b null atria. 
Right atria, Scn2b null: N=9; WT: N=9, Left atria, Scn2b null: N=7; WT: N=7. 
Significance determined using Student’s T test. 
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Figure 15 AP recordings from right atrial myocytes. 
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A. No differences between genotypes were found in AP amplitude, AP maximum 
upstroke velocity, or resting membrane potential. B. APD50-90 were prolonged in the 
Scn2b null group (* P<0.05). C. Representative superimposed AP traces from Scn2b 
null and WT myocytes. D. Distribution of the APD90 data paced at 1 Hz from ventricular 
and atrial myocytes. The increase in ventricular APD observed in Scn2b nulls is 
homogenous, shifting the entire data set upward. In contrast, APD lengthening in atrial 
myocytes is heterogeneous, resulting in a more dispersed distribution of the data set 
(Scn2b null: N=4 mice n=13 cells; WT: N=5 mice n=12 cells, Student’s T test). 
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Increased fibrosis in Scn2b null right atrium 
Evidence in the literature connects cardiac VGSC dysfunction to fibrosis174–176.  To 
assess the level of fibrosis in our Scn2b null model, the posterior walls of both right and 
left atria were sectioned in the coronary plane and stained using Masson’s trichrome 
protocol. I observed an increased level of fibrosis in the right, but not the left Scn2b null 
atria compared to WT (Fig. 16 A-B). I propose that the fibrotic tissue deposited in the 
Scn2b null right atrial interstitial space creates anatomical substrates for wavebreaks as 
well as anchor points for rotors, and may explain transitions from atrial fibrillation to 
atrial flutter in the null animals (e.g. Fig. 16C). 
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Figure 16 Increased fibrosis in Scn2b null right atrium. 
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A. Masson’s trichrome staining shows increased fibrosis (blue) in Scn2b null right atria 
but not left atria compared to WT.  B. Quantification of fibrosis using a scoring system 
(p=0.002, Mann-Whitney Rank Sum Test). Six 8-9 month old animals were included 
from each genotype. C. Transition of atrial fibrillation to atrial flutter in Scn2b null atrium. 
Increased levels of fibrosis are proposed to provide anchoring points for rotors 
underlying the transition. 
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Discussion 
 
AF in BrS  
AF is the most prevalent clinical arrhythmia177, with even higher incidence in BrS 
patients compared to the general population (5.7%-53% vs. 1%-2%, respectively) 178–182. 
Both loss- and gain-of-function mutations in SCN5A have been linked to familiar AF 172. 
The two known AF patients with SCN2B mutations exhibited saddleback type ST 
segment elevation in the right precordial leads, further supporting a close connection 
between BrS and AF48. Loss of SCN5A function has been shown to both facilitate and 
inhibit AF in different BrS patients183. Decreased atrial conduction velocity is predicted 
to favor AF due to shortened wavelength, while concomitant lowered excitability is 
thought to reduce AF triggers. Thus, SCN5A-linked BrS may provide AF substrates 
rather than increase spontaneous AF occurrence. In line with this hypothesis, the 
incidence of spontaneous AF does not differ between patients with and without SCN5A 
mutations 181–183. In contrast, SCN5A-linked BrS patients exhibit longer intra-atrial 
conduction time, increased left atrial volume index, and higher AF inducibility (46.7% vs 
20.7%) 181,182. Further, the prevalence of persistent AF is higher in this subgroup of 
patients183. In one of the lone paroxysmal AF patients with a SCN2B mutation, left atrial 
enlargement was identified48. Thus, in more advanced AF, which often involves 
electrical and anatomical remodeling, VGSC α or β subunit gene mutations may 
facilitate disease progression by providing arrhythmogenic substrates.  
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I found atrial conduction to be unaltered in Scn2b null mice. There were no differences 
in AP maximum upstroke velocity in single cell recordings, no differences in conduction 
velocity measured by optical mapping of atrial tissue, and no differences in P wave 
duration or AH interval acquired in ECG and intracardiac recording. These results 
suggest that, unlike in the ventricle, atrial INa is unchanged in response to Scn2b 
deletion. Instead, loss of β2 has extensive effects on AP repolarization and tissue 
remodeling. The APD was increased in a heterogeneous fashion in Scn2b null atrium, 
resulting in larger repolarization dispersion. In addition, higher levels of fibrosis were 
found preferentially in Scn2b null right atrium. These changes are proposed to provide 
electrical and anatomical substrates that favor AF, and thus explain the higher 
susceptibility of Scn2b null atrium to AF. The proposed increased heterogeneity of 
Scn2b null atrium is supported by our finding that the number, frequency, location, and 
organization of rotors are highly dynamic and complex.  
 
Fibrosis in Scn2b null atria 
Links between VGSC dysfunction and fibrosis have been demonstrated in the heart. For 
example, TGF-β1-mediated fibrosis is triggered by Scn5a disruption, suggesting a 
common signaling pathway176. In addition, VGSC β2 subunits are substrates for 
sequential cleavage by BACE-1 and -secretase78.  The cleaved intracellular domain of 
β2, at least in neurons, translocates to the nucleus to participate in transcriptional 
regulation of VGSC α subunits and possibly other genes.  Thus, the cleaved β2 
intracellular domain may normally regulate genes that inhibit fibrosis in the heart.  In the 
absence of β2, fibrotic gene expression may proceed unchecked. Interestingly, fibrosis 
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is increased in Scn2b null right atrium but not in left atrium. This chamber preference 
was also seen in a TGF- β1 overexpression model of atrial fibrosis and AF184, implying 
that the TGF- β1 signaling pathway may also be involved in the mechanism of fibrosis in 
Scn2b null hearts. This question is, however, beyond the scope of the present study. 
 
Role of β2 in cellular electrophysiology  
Scn2b deletion results in a ~50% reduction in total INa density as well as a 
hyperpolarizing shift and altered slope factor of the voltage-dependence of activation in 
mouse ventricular myocytes, suggesting that β2 subunits have dramatic effects on 
ventricular INa in vivo. While heterologous expression studies are a convenient first 
approach to gain structure-function information129, co-expression of β2 with NaV1.5 in 
heterologous cell lines has little to no effect on INa density, kinetics, or gating 
properties12,22,48. This confusion between in vivo and in vitro results raises concerns 
about how to interpret data derived from heterologous systems when modeling 
electrophysiological properties of myocytes. To add to this complexity, repolarization, 
rather than depolarization, was more severely affected in Scn2b null atrial myocytes 
compared to Scn2b null ventricular cells, implying cell type specific functional roles of β2, 
possibly through differential multi-protein complex formation or differences in post-
transcriptional modification in atrium vs ventricle. Solving these important issues will be 
critical to completely understanding the roles of VGSC α and β subunits in cardiac 
physiology. 
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CHARPTER V 
Conclusion and Future Directions 
 
Voltage-gated sodium channels (VGSCs) are critical for impulse initiation and 
propagation in excitable cells, including nerve and muscle. The ion-conducting VGSC α 
subunits are modulated by two β subunits that do not form the pore but play essential 
roles in electrical signal transduction. VGSC β subunits signal through multiple 
pathways on multiple time scales in vivo and, at least for β1, are essential for life. In 
addition to regulating sodium current, β subunits associate with potassium channels and 
play non-ion-conducting roles as cell adhesion molecules (CAMs) that participate in cell-
cell coupling and macromolecular complex formation. Mutations in genes encoding 
VGSC β subunits disrupt both sodium and potassium channel complexes as well as 
cell-cell communication, leading to heart and brain diseases that can be catastrophic. In 
my PhD thesis work, I investigated the physiological roles of VGSC β2 in the heart using 
the Scn2b null mouse model. Scn2b deletion results in electrical abnormalities in both 
atrium and ventricle. Defects in both depolarization and repolarization were observed in 
the ventricle, similar to human Brugada syndrome (BrS). We also found an increased 
propensity of the Scn2b null atrium to atrial fibrillation (AF), consistent with the higher 
prevalence of AF in human BrS patients. We conclude that Scn2b null mice are a useful 
new tool for modeling cases of human BrS with susceptibility to atrial arrhythmia. Scn2b 
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null mice also appear to have altered autonomic control, adding neuronal complexity to 
this unique cardiac arrhythmia model. This study provides insight into the role of VGSC 
β2 in maintaining normal cardiac electrical activity, introduces a murine model that will 
be useful in understanding the mechanism of human BrS, and provides a novel 
perspective on the connection between BrS and atrial fibrillation in patients who carry 
VGSC gene mutations. 
  
β2 subunits modulate K+ channels? 
Ventricular and atrial APDs were both prolonged in Scn2b null myocytes, but in different 
fashions, raising the possibility that repolarizing currents such as K+ currents were also 
modulated by β2.   β subunits are multifunctional molecules that are not specific to 
VGSC complexes. β1 co-assembles with and modulates the properties of the KV4.x 
subfamily of channels that underlie Ito  in heart and IA in brain37,38,110. The SCN1B 
mutation p.R214Q, which selectively affects β1B and not β1, is proposed to contribute 
to the arrhythmogenesis of BrS by concomitantly decreasing INa and increasing Ito36. 
Thus, profiling ionic currents in Scn2b null myocytes will provide important insights into 
the potential relationship of β2 with other cardiac ion channels. Direct channel 
modulation, transcriptional modification, trafficking, or compensatory effects are putative 
mechanisms of how β2 may affect other channels. Filling these knowledge gaps will not 
only reveal novel functions of β2, but also provide alternative explanations for 
arrhythmogenesis.  
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Atrial cardiomyopathy? 
Scn2b null atria exhibited higher susceptibility to atrial tachyarrhythmia due to electrical 
as well as anatomical remodeling. However, I found that these mice had not yet 
developed spontaneous AF.  According to the definition provided in the 2007 ESC 
statement on classification of cardiomyopathies, cardiomyopathies are defined by 
structural and functional abnormalities of the ventricular myocardium that are 
unexplained by flow-limiting coronary artery disease or abnormal loading conditions185. 
Though the definition does not include atria, I propose that the atrial phenotype of 
Scn2b null mice could be practically defined as atrial cardiomyopathy. The difference 
between AF-induced atrial remodeling and primary atrial cardiomyopathy is that fibrosis 
in the Scn2b null is due to a direct response to gene deletion rather than the auto-
reinforcing property of AF. Nevertheless, fibrosis in each scenario may share common 
signaling pathways. Thus, understanding the role of β2 in fibrosis will be beneficial to 
developing new therapeutic approaches to the AF. TGF-β1-mediated fibrosis is 
triggered by Scn5a disruption in the heart, suggesting links between VGSC dysfunction 
and fibrosis176. The TGF-β1/SMAD pathway is also involved in structural remodeling in 
AF186. Fibrosis promotes AF by interrupting fiber continuity and interacting with 
myocytes187. Novel upstream approaches such as interfering with the TGF-β1 signaling 
pathway may prevent atrial fibrillation progression188, in which case, VGSC β2 could be 
a putative target.   
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Role of β2 in the autonomic nervous system? 
Altered autonomic control was implied in Scn2b null mice. We showed previously that 
β2 is extensively expressed in the central and peripheral nervous systems, where it 
modulates neuronal sodium channels104,105,169, and potentially contributes to autonomic 
control of the heart. The autonomic nervous system plays an important role in the 
modulation of cardiac electrophysiology and arrhythmogenesis189. A detailed 
investigation of the role of β2 in autonomic regulation will be essential for us to have a 
full picture of arrhythmogenesis in patients who carry SCN2B mutations. 
 
Large-animal models are a better alternative for arrhythmia studies 
Although Scn2b null mice recapitulated the pathophysiology of BrS and allowed us to 
have greater insight into the mechanism of this disease, mice cannot phenocopy human 
BrS ECG manifestations due to poorly defined J-points and lack of ST segments. These 
disparities in ECG waveforms result from distinct action potential morphologies between 
human and mouse myocytes150. The J-point in human ECGs is postulated to be 
equivalent to the end of J wave in the mouse ECG, corresponding to the moment when 
the potential is equal throughout the heart in the frontal plane, according to a study by 
Boukens et al at under baseline conditions190. However, in mice carrying Scn5a BrS 
mutatiosn or challenged by the VGSC blocker, ajmaline, the QRS is no longer an 
accurate measure of conduction time. Subsequently, the end of the J wave no longer 
represents the moment of baseline condition. Thus, genetically manipulated larger 
animal models, which share more common features with humans including heart size 
and cardiac electrophysiology, should be the focus of future studies. For example, 
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transgenic rabbits that carry loss-of function mutations in HERG potassium channels 
successfully model human Long QT syndrome type 2 (LQT2)191. Genetically engineered 
pig hearts carrying a BrS-associated SCN5A nonsense mutation (SCN5AE558X/+) 
exhibited conduction defects and arrhythmias192, phenocopying many aspects of human 
BrS. So far, all human cardiac arrhythmia associated SCN2B mutations are 
heterozygous, thus, investigating large-animal hearts carrying one SCN2B mutant allele 
will allow electrophysiological and molecular studies of arrhythmic mechanisms.  
 
iPSC-CM as cellular models for ion channel mutation study  
As discussed in Chapters I and IV, there are critical limitations to using heterologous 
expression systems as cellular in vitro models of arrhythmia. Results from these 
experiments may misguide us in attributing molecular mechanism of arrhythmia to 
channel electrophysiological alterations that are only observable in heterologous 
systems. Besides, low penetrance and variable expressivity of ion channel mutations, 
which may stem from epigenetic factors, age, gender, or genetic modifiers, add 
complexity in understanding pathogenesis. Thus, utilizing a cellular model that can 
recapitulate a patient’s unique genetic background as well as maintain all interacting 
proteins, such as human induced pluripotent stem cell derived cardiomyocytes (iPSC-
CMs) will be valuable to future work127. In addition, patient-specific iPSC models will be 
invaluable tools for drug screening128 and  the development of individualized therapies. 
An important next step to continue my SCN2B work would be to collect human skin 
biopsy samples from diseased SCN2B mutation carriers, reprogram them to 
pluripotency, and then differentiate them to cardiomyocytes for functional assessment. 
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A better knowledge of genotype-to-phenotype correlations will necessarily become the 
basis not only for mechanistic studies but also for more precise risk stratification and 
prognosis estimation for specific patients. 
 
β2: A future therapeutic target for BrS? 
The implantation of an ICD is the only proven effective therapeutic strategy for the 
prevention of sudden cardiac death (SCD) in BrS patients193. However, this therapy has 
a high complication rate, in which the major difficulty is inappropriate shocks194–196. If a 
BrS patient concomitantly has atrial arrhythmia, this can be an important cause of 
inappropriate ICD shocks197. Moreover, patients who receive ICD shocks may also 
develop psychological distress and have reduced quality of life (QoL)198. Thus, gene 
therapy may potentially be the ultimate solution to provide long term relief to 
channelopathy patients. Recently, single delivery of an Adeno-Associated Viral (AAV) 
construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic 
polymorphic ventricular tachycardia was demonstrated to cure the disease from birth to 
advanced age199. Similarly, as an important multi-functional modulatory molecule in ion 
channel macromolecular complexes, gene transfer of WT SCN2B may be efficacious to 
BrS patients who carry VGSC loss-of-function mutations.  
 
Summary 
Work presented here provides a broad view of the electrophysiological roles of β2 in the 
heart as well as mechanistic insights into ventricular and atrial arrhythmogenesis, 
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bridging molecular findings with clinical consequences in a murine model. My work 
highlights the importance of this multi-functional molecule and lays the groundwork for 
subsequent studies in large animal models and patient-derived iPSC-CMs. Future 
studies should include investigating the impact of β2 on other cardiac and autonomic 
nervous system ion channels, using novel animal and cellular models, elucidating the 
role of β2 in fibrosis, and developing gene therapy for primary cardiac arrhythmia. 
Elucidating the multi-faceted functions of β2 in the heart not only advances our 
understanding of the mechanism of arrhythmia, but also advances personalized therapy 
for arrhythmia in the new era of precision medicine. 
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CHAPTER VI 
Methods 
 
Animals  
Male and female Scn2b null mice, congenic on the C57BL/6J background for over 20 
generations, were used at the ages indicated in the figure legends. Mouse genotyping 
was described previously104. 
 
Ethics statement  
This study was carried out in accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol 
was approved by the University Committee on the Use and Care of Animals at the 
University of Michigan. All efforts were made to minimize animal suffering. 
 
Cell isolation  
Ventricular myocyte isolation for INa recording 
WT and Scn2b null cardiac myocytes were acutely isolated from 2-3 month old mice of 
both genders using a protocol described in Auerbach et al200. In brief, hearts were 
 94 
isolated and were cannulated with perfusion buffer (37°C, 3 ml/min). After blood was 
cleared out, Type-II collagenase (0.87 mg/ml, Worthington Biochemical), trypsin (0.14 
mg/ml), and 12 µM CaCl2 were added to the perfusion buffer for digestion. The 
digestion time last for 3-4 min. The lower two-thirds of the ventricles (including both left 
and right ventricle) were isolated and minced in the digestion buffer into small pieces. 
Reaction was then stopped by stopping buffer, which included perfusion buffer plus 
10% fetal bovine serum and 12.5 µM CaCl2. Ca2+ concentration was finally increased to 
1mM incrementally by 5-step addition of CaCl2 at 37 °C. Only quiescent myocytes were 
chosen for electrophysiological recordings. 
 
Right ventricular outflow track (RVOT) myocyte isolation 
RVOT myocyte isolation was similar to that described above. However, instead of 
isolating the lower two-thirds of the heart, the RVOT anterior free wall corresponding to 
the slowed conduction area in optical mapping (see below), were cut from 2-4 month old 
male mice. Tissues were minced in digestion buffer followed by steps similar to those 
described above. 
 
Isolation of atrial myocytes 
This procedure was similar to the ventricular myocyte isolation described above but with 
the following changes: 1.25g/25ml Liberase TM (Roche) was added to the digestion 
buffer during perfusion. Digestion time was modified to 12-18 min. 2-3 month old mice 
of both genders were used. To minimize the known AP heterogeneity between left and 
right atria201, only the right atrial region to the right of the crista terminalis was isolated.  
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Single Cell Electrophysiology 
Standard voltage and current clamp techniques were used to assess the effects of 
Scn2b deletion on cardiac INa and AP properties, respectively. Borosilicate glass 
pipettes with resistance of <3MΩ for INa and 3-5 MΩ for AP recordings were used. Data 
were acquired using an Axopatch 200B amplifier and Axopatch 700B (Molecular 
Devices, USA). The data were analyzed using pCLAMP9-10 (Molecular Devices, USA) 
and custom AP analysis software (National Instruments LabView, USA) 
 
Voltage Clamp Recordings 
Voltage clamp INa recordings were performed at room temperature (21–22°C). The 
extracellular solution contained (in mM): 5 NaCl, 1 MgCl2, 1 CaCl2, 0.1 CdCl2, 11 
Glucose, 132.5 CsCl, and 20 HEPES. The filling solution contained (in mM): 5 NaCl, 
135 CsF, 10 EGTA, 5 MgATP, and 5 HEPES. After sealing and breaking into the cells, 
series resistance compensation (prediction and correction <75%) and leak subtraction 
were applied. Transient and persistent INa density, INa inactivation time, and the voltage 
dependence of INa conductance were obtained at voltage between -100 and +30 mV 
using a holding potential of -120 mV. Every step last for 200 ms, with 2800 ms 
interpulse time. The voltage dependence of INa availability was determined by holding at 
various voltages (-160 mV to 0 mV, 5 mV increments, 200 ms duration) and stepping to 
-40 mV (30 ms), with 2770 ms interpulse intervals at -120 mV. Boltzmann function was 
fitted to gain the normalized voltage dependence of INa availability. And then differences 
in the V½ and slope factor were compared between groups. The time dependence of INa 
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recovery was assessed by using two evoking pulse (P1 and P2) at -30mV with various 
interpulse interval. Holding potential was at -120 mV. The time dependence of INa 
recovery was calculated by P2/P1 at each time point, and these results were fit to a 
single exponential function. The rate of INa inactivation was fit to a double exponential 
function. Persistent INa, measured 50-52 ms after the voltage step, when the current 
amplitude was stable.  
 
Current Clamp Recordings 
Current clamp recordings of APs were acquired at 37°C in standard Tyrode solution (in 
mM): 148 NaCl, 0.4 NaH2PO4, 1 MgCl2, 5.4 KCl, 1 CaCl2, 5.5 glucose, 15 HEPES. The 
internal solution included (in mM): 140 KCl, 5 EGTA-KOH, 10 HEPES. Incremental 
amounts of current (100 pA steps, 1 ms) were used to map the threshold of current to 
evoke an AP. Then, 1.5-fold of that current was used for AP recordings at different 
pacing cycle lengths (200-1000 ms). Only cells with a diastolic membrane potential 
more negative than -65 mV were included.  
 
Super-resolution scanning patch clamp  
This method combined scanning ion conductance microscopy (SICM) with cell-attached 
patch clamp technology for recording of ion channels at a particular subcellular location. 
A detailed description of this technique can be found in the previous work of Bhargava 
et al132. Briefly, after mapping the topography of the cardiomyocyte surface with SICM, 
the pipette tip was clipped against the bottom of the dish until appropriate resistence 
was reached. Then the pipette was repositioned to spatial coordinates that were 
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selected based on the topography image recorded. Pipette was lowered to the selected 
location to record sodium channels in the cell-attached configuration. 
 
Optical Mapping 
Ventricular mapping  
3-6 month old male mice were heparinized (0.5 U/g i.p.) and then euthanized. The heart 
was excised and placed in ice-cold cardioplegic solution, then it was cannulated and 
retrogradely perfused through the aorta with warm (36.8 ± 0.3 °C), oxygenated (100% 
O2) Tyrodes solution containing (in mM) 130 NaCl, 1.2 NaH2PO4, 1.0 MgCl2, 4.0 KCl,1.8 
CaCl2, 5.6 glucose, and 25.0 HEPES, pH 7.4. 20-30 min The preparation was 
equilibrated for 20-30min before any pacing maneuver. Volume-conducted ECGs were 
acquired in pseudo lead 2 configuration and digitized at 1 KHz (MiniDigi1A digitizer and 
AxoScope software; Axon Instruments). The preparation was then perfused with 7 μM 
Blebbistatin (Cayman Chemical), a mechanical uncoupler, to immobilize the heart. A 
voltage-sensitive fluorescent dye, 100 μM Di-4-ANEPPS (Life Technologies), was used 
to stain the heart. A CCD camera with 80 × 80 pixel (SciMeasure) was anchored to a 
SMZ-1000 dissection microscope (Nikon). This high-resolution image system can image 
a 6.4 × 6.4-mm area at 800 frames per second, which providing a spatial resolution of 
80 μm per pixel. The heart was positioned under the microscope allowing the camera to 
capture the anterior ventricular epicardium including left ventricle, right ventricle, and 
apex. Optical movies (4 s) were acquired under 532-nm fluorescence excitation (argon 
laser, 1 W) and 640 ± 20 nm emission. Optical movies were recorded at baseline and at 
RV apex pacing. The pacing cycle lengths was175 ms to 100 ms. Analysis was 
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performed using custom-made software. To visualize arrhythmia, phase maps were 
generated as described elsewhere101. 
 
Atrial Mapping 
This procedure was similar to ventricular mapping. 8-9 month old mice of both genders 
were used. Instead of cannulation, we excised the whole atrium along the AV rings 
(mitral and tricuspid), pinned the preparation to a sylgard gel coated dish and 
superfused the tissue with warm (36.8 ± 0.3 °C), oxygenated (100% O2) Tyrodes 
solution. The CCD camera was positioned to face the posterior wall of both atria. 
Optical movies were recorded at baseline and at progressively shorter basic cycle 
lengths (125 ms to 100 ms) during right atrium appendage pacing. Arrhythmia 
inducibility was assessed by applying 2 atrial electric stimulations (bursting pacing at 
66.67 HZ for 5 or 10 seconds) before and after the carbachol (Cch, 300 nM) 
administration.   
 
ECG and intracardiac recording 
In vivo studies were performed in two sets of mice. One set included 2-3 month old mice 
and were anesthetized by Avertin (1.2%, 0.23ml/10g i.p. prepared from 2,2,2-
tribromoethanol and 2-methyl-2-butanol, Sigma). The other set included 7-9 month old 
mice that were anesthetized with isofluorane (induction period 5.0% vol. maintenance, 
2.0% vol. isofluorane in 70%N2/30%O2 for further intracardiac recording). Following the 
achievement of surgical anesthesia, mice were placed onto a temperature-regulated 
operating table. Platinum electrodes (Natus Neurology) were inserted subcutaneously in 
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the limbs and connected to a DSI digital communication module and then to the DSI 
ACQ-7700 - acquisition interface (Data Sciences International) for a standard lead-II 
ECG. Standard ECG parameters (HR, P wave duration and PR interval, QRS duration, 
QT interval) were analyzed under stable baseline conditions with 1.5% vol. isofluorane. 
A 1.1 French octapolar stimulation-recording catheter (FTS-1113A-0518, Science) was 
inserted through the jugular vein and advanced into the right atrium and ventricle. 
Programmed electrical stimulation was assessed to determine the basal sinus node 
recovery time (SNRT) by applying S1S1 protocol at 120 ms and 90 ms of cycle length 
(CL), while the atrial refractory period (AERP), atrio-ventricular nodal effective refractory 
period (AVERP), and ventricular refractory period (VERP) were estimated by delivery of 
a S1-S1-S2 protocol with a fixed S1 (100ms and 80ms CL) and reducing S2 every 2 ms. 
Arrhythmia inducibility was assessed by apply 12-18 atrial bursts of pacing (50 HZ for 2 
or 5 sec) before and after the i.p. carbachol (Cch, 50 ng/g) application. AF was defined 
as the occurrence of rapid and fragmented atrial electrograms (lack of regular P waves) 
with irregular AV-nodal conduction and ventricular rhythm lasting at least 1 sec. The 
entire procedure was completed in less than 2 h. 
 
Assessment of Fibrosis  
Atria from 8-9 month old mice of each gender were collected for histology. Only 
posterior walls of each side were collected. For the right atrium, tissue that was to the 
right of the crista terminalis was excised to eliminate collection of SA nodal tissue. 
Tissues were fixed in 10% formalin and submitted to the University of Michigan Unit for 
Laboratory Animal Medicine In-vivo Animal Core facility for sectioning and further 
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analysis using Masson’s Trichrome staining. Tissue sections were analyzed for the 
degree of fibrosis using Aperio© software. The color deconvolution algorithm was used 
to quantify the connective tissue component of each section. The slides were viewed on 
ImageScope©. The intensity of the blue staining was measured in areas outlined by a 
veterinary pathologist. The area and intensity of the staining were scored as weak, 
medium, or dark according to windows set by calibration of the slides using the 
algorithm. To account for differences in staining intensity and distribution between slides, 
a total score was derived from (3 x strong) + (2 x medium) + (1 x week) intensity, as 
recommended by the software manufacturer. 
 
Statistics 
Results are expressed as mean ± SEM. Statistical significance was evaluated using t 
test, Mann-Whitney rank sum test, or Fisher’s exact test, as indicated in the figure 
legends. P<0.05 was considered statistically significant. All calculations were performed 
using SigmaPlot 11.2 (Systat Software Inc, San Jose California USA).   
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